oxonic acid has been researched along with Local Neoplasm Recurrence in 311 studies
Oxonic Acid: Antagonist of urate oxidase.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events." | 9.20 | Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015) |
| "To date, gemcitabine-based or fluoropyrimidine-based regimens are recommended for unresectable advanced biliary tract cancer." | 9.20 | Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. ( Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K, 2015) |
| "A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)." | 9.20 | Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015) |
| "Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC)." | 9.20 | Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. ( Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D, 2015) |
| "A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer." | 9.17 | A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H, 2013) |
| "We aimed to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the addition of S-1, an oral fluorouracil derivative, to gemcitabine and cisplatin combination therapy, which is the current standard treatment for advanced biliary tract cancer." | 9.16 | Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). ( Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D, 2012) |
| "We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination chemotherapy for the treatment of patients with advanced biliary tract cancer." | 9.15 | A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. ( Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K, 2011) |
| "To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer." | 9.15 | A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 9.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens." | 9.12 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. ( Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC, 2006) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 8.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC)." | 8.02 | Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. ( Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021) |
| "5-Fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) therapy and 5-FU, leucovorin, and irinotecan (FOLFIRI) therapy are standard chemotherapies to treat advanced/recurrent colorectal cancer." | 7.80 | Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer. ( Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014) |
| "Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC)." | 7.78 | An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. ( Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H, 2012) |
| "Patients with HER2-negative and endocrine treatment-resistant breast cancer with metastasis or recurrence after surgery were randomly assigned to receive first-line taxane or S-1." | 5.27 | Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer. ( Fukuda, T; Hagiwara, Y; Kawahara, T; Mukai, H; Ohashi, Y; Shimozuma, K; Shiroiwa, T; Taira, N; Uemura, Y; Watanabe, T, 2018) |
| "We investigated the efficacy and safety of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium (TS-1) in patients with metastatic and recurrent breast cancer (MRBC), and the association between irinotecan metabolizing enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) gene polymorphisms and adverse events." | 5.20 | Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer. ( Fujii, T; Iwakuma, N; Kakuma, T; Mishima, M; Otsuka, H; Shirouzu, K; Takahashi, R; Takenaka, M; Tanaka, M; Toh, U, 2015) |
| "To date, gemcitabine-based or fluoropyrimidine-based regimens are recommended for unresectable advanced biliary tract cancer." | 5.20 | Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer. ( Abe, K; Aiba, K; Futagawa, Y; Hata, D; Okui, N; Sakamoto, T; Shiba, H; Uwagawa, T; Yanaga, K, 2015) |
| "A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC)." | 5.20 | Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer. ( Cho, JW; Choi, DR; Ha, HI; Han, B; Jeon, JY; Jung, JY; Kim, HS; Kim, HY; Kim, JH; Kim, MJ; Kwon, JH; Oh, HS; Park, CK; Song, H; Zang, DY, 2015) |
| "Capecitabine and S-1 are orally administered fluorinated pyrimidines with high-level activity against metastatic breast cancer (MBC)." | 5.20 | Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial. ( Ariyoshi, K; Iwase, S; Kawaguchi, T; Kitamura, K; Miyaji, T; Nagumo, Y; Odagiri, H; Sueoka, N; Teramoto, S; Tsubota, Y; Yamaguchi, T; Yamamoto, C; Yamamoto, D, 2015) |
| "A number of clinical trials, including the FIRIS study, have shown that S-1 plus irinotecan (IRIS) is safe and effective in patients with colorectal cancer." | 5.17 | A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ikeda, M; Mizushima, T; Mori, M; Murata, K; Nezu, R; Ohnishi, T; Ohue, M; Ota, H; Sekimoto, M; Takemasa, I; Tanaka, N; Uemura, Y; Yamamoto, H, 2013) |
| "We aimed to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of the addition of S-1, an oral fluorouracil derivative, to gemcitabine and cisplatin combination therapy, which is the current standard treatment for advanced biliary tract cancer." | 5.16 | Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002). ( Ajiki, T; Fujiwara, Y; Hatano, E; Ioka, T; Kanai, M; Kobayashi, S; Kodama, Y; Nagano, H; Sakai, D, 2012) |
| "We aimed to evaluate the efficacy and safety of gemcitabine/S-1 combination chemotherapy for the treatment of patients with advanced biliary tract cancer." | 5.15 | A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer. ( Asada, M; Chiba, T; Fukushima, M; Hamada, A; Hatano, E; Ikai, I; Inoue, N; Kanai, M; Matsumoto, S; Mori, Y; Niimi, M; Nishimura, T; Nitta, T; Osaki, Y; Suzuki, C; Tada, S; Taura, K; Tsumura, T; Uemoto, S; Yanagihara, K; Yasuchika, K; Yazumi, S; Yoshimura, K, 2011) |
| "To investigate the combination of S-1 and irinotecan (CPT-11) as an alternative to infusional 5-fluorouracil/leucovorin plus CPT-11, we performed a phase I trial to determine the maximum tolerated dose, recommended dose (RD), and dose-limiting toxicities (DLTs) in patients with metastatic or recurrent colorectal cancer." | 5.15 | A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer. ( Chang, HM; Choi, YH; Hong, YS; Kang, YK; Kim, TW; Lee, JL; Lee, SS; Ryu, MH, 2011) |
| "This phase II study was designed to evaluate the efficacy and safety of oral fluoropyrimidine S-1 plus irinotecan (IRIS regimen) in patients with previously untreated metastatic colorectal cancer." | 5.15 | Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302). ( Asaka, M; Fukushima, H; Iwanaga, I; Komatsu, Y; Kudo, M; Meguro, T; Saga, A; Sakata, Y; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2011) |
| "This is the first phase II study of S-1 monotherapy for patients with metastatic colorectal cancer after failure of both irinotecan- and oxaliplatin-containing regimens." | 5.12 | A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. ( Ahn, JB; Cho, BC; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Roh, WJ; Yoo, NC, 2006) |
| " Major toxicities were leukopenia (38%), anorexia (27%), increased total bilirubin concentration (25%) and diarrhea (24%)." | 5.10 | [Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003) |
| "A combination of irinotecan (CPT-11) with continuous intravenous infusions of (infusional) 5-fluorouracil (5-FU) and Leucovorin (LV) is one of the standard treatments for advanced colorectal cancer patients." | 4.83 | [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer]. ( Goto, A, 2006) |
| "Background Combination therapy of gemcitabine with cisplatin (GC) is a standard first-line therapy for unresectable or recurrent biliary tract cancer (BTC)." | 4.02 | Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer. ( Andoh, A; Fukutomi, A; Fushiki, K; Hamauchi, S; Inoue, H; Kawakami, T; Machida, N; Onozawa, Y; Shirasu, H; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T, 2021) |
| "Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC)." | 3.91 | S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma. ( Boku, N; Hirano, H; Honma, Y; Ito, T; Iwasa, S; Kato, K; Okita, N; Shoji, H; Takashima, A, 2019) |
| " The first group was given tailored CPT-11, adjusting individual optimal dosage using toxicity-based grading as an index in combination with TS-1, and the second group was given standard TS-1 treatment." | 3.81 | [A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)]. ( Kitajima, M; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Toge, T, 2004) |
| "We examined the completion rate, safety, and adverse events in patients with T2N0 glottic carcinoma who received chemoradiotherapy with S-1 (tegafur-gimeracil-oteracil potassium)." | 3.80 | Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study. ( Higashino, M; Ichihara, S; Kawata, R; Lee, K; Nishikawa, S; Uesugi, Y, 2014) |
| "5-Fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) therapy and 5-FU, leucovorin, and irinotecan (FOLFIRI) therapy are standard chemotherapies to treat advanced/recurrent colorectal cancer." | 3.80 | Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer. ( Abe, S; Egawa, Y; Futami, K; Higashi, D; Hirano, K; Hirano, Y; Inoue, R; Maekawa, T; Mikami, K; Miyake, T; Miyazaki, M; Takahashi, H; Uwatoko, S; Yamamoto, S, 2014) |
| "Gemcitabine is widely used as a first-line therapy for biliary tract cancer (BTC)." | 3.78 | An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer. ( Egawa, S; Katayose, Y; Kitamura, Y; Masuda, K; Motoi, F; Naitoh, T; Nakagawa, K; Ohtsuka, H; Onogawa, T; Rikiyama, T; Unno, M; Yamamoto, K; Yoshida, H, 2012) |
| "High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer." | 3.74 | [Evaluation of combination therapy of high-dose toremifene and oral chemotherapy]. ( Murakami, S; Yamamoto, Y, 2007) |
| "The prognosis of stage III gastric cancer (GC) is not satisfying and the specific chemotherapy regimens for GC of stage IIIC based on the 8th edition of the UICC/AJCC TNM staging system are still inconclusive." | 3.11 | Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. ( Feng, T; Li, C; Mei, Y; Shi, M; Yan, C; Yan, M; Yuan, H; Zhang, J; Zhu, Z, 2022) |
| "Although chemotherapy for metastatic colorectal cancer (mCRC) has improved, the standard chemotherapy regimens for patients with RAS wild-type mCRC remain debated." | 3.01 | Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study). ( Doki, Y; Eguchi, H; Haraguchi, N; Ide, Y; Kim, H; Kudo, T; Matsuda, C; Mizushima, T; Murata, K; Nakata, K; Nishizawa, Y; Okamura, S; Satoh, T; Uemura, M, 2021) |
| " Most frequent (>10%) grade 3/4 treatment-related adverse events were neutropenia (14." | 2.90 | Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A ( Azuma, M; Boku, N; Chen, LT; Cho, H; Chung, HC; Fumita, S; Hara, H; Kang, WK; Kang, YK; Kato, K; Komatsu, Y; Lee, KW; Minashi, K; Ryu, MH; Tsuda, M; Yamaguchi, K, 2019) |
| "The benefit of systemic treatments in esophageal squamous cell carcinoma (ESCC) which has progressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established." | 2.90 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. ( Ba, Y; Bai, Y; Cheng, Y; Fan, Q; Feng, J; Hu, C; Huang, J; Li, J; Liu, Y; Lu, P; Ma, C; Wang, X; Wen, L; Wu, L; Xu, B; Yuan, X; Zhang, S, 2019) |
| "Recent gastric cancer clinical trials have aimed to establish the efficacy of combination therapy over monotherapy, however, the role for genomic biomarkers in these trials has remained largely unexplored." | 2.87 | Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial. ( Das, K; Imamura, H; Nishikawa, K; Sugimoto, N; Taguri, M; Tan, P; Tsuburaya, A; Yoshida, K, 2018) |
| "Sixteen patients (48." | 2.87 | A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease. ( Atagi, S; Azuma, M; Goto, H; Haku, T; Hanibuchi, M; Kakiuchi, S; Kawano, H; Kondo, M; Nishioka, Y; Nokihara, H; Ogushi, F; Otsuka, K; Sakaguchi, S; Shimizu, E; Toyoda, Y, 2018) |
| " This study evaluated the efficacy of intensity modulated radiotherapy in combination with gemcitabine and S-1 as neoadjuvant chemoradiotherapy (NACRT) for borderline-resectable pancreatic cancer with arterial involvement (BR-A)." | 2.84 | A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement. ( Hijikata, Y; Hosokawa, Y; Kasuya, K; Katsumata, K; Nagakawa, Y; Nakajima, T; Nakayama, H; Sahara, Y; Takishita, C; Tokuuye, K; Tsuchida, A, 2017) |
| "However, the high recurrence rate makes gastric cancer difficult to cure by surgery alone." | 2.82 | A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, JE; Kim, KR; Nam, TK; Park, YK; Ryu, SY; Shim, HJ, 2016) |
| "Patients aged 20-80 with stage II/III rectal cancer undergoing curative surgery without preoperative therapy were randomly assigned to receive UFT (500-600 mg/day on days 1-5, followed by 2 days rest) or S-1 (80-120 mg/day on days 1-28, followed by 14 days rest) for 1 year." | 2.82 | A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC). ( Baba, H; Emi, Y; Hamada, C; Ikejiri, K; Kakeji, Y; Kotake, M; Maeda, K; Maehara, Y; Matsuda, C; Matsuda, H; Munemoto, Y; Murata, A; Oki, E; Saji, S; Sasaki, K; Suenaga, T; Yoshida, K, 2016) |
| "Irinotecan was administered intravenously over the course of 90 minutes on day 1, and S-1 was given orally in 2 divided doses from days 1 to 14 of a 21-day cycle." | 2.82 | Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy. ( Kimura, T; Kobayashi, E; Kozasa, K; Mabuchi, S; Owa, T; Tomimatsu, T; Tsutui, T; Yamashita, M; Yoki, T; Yokoi, E, 2016) |
| " The safety and dosage of S-1 combined with postoperative radiotherapy have not yet been evaluated." | 2.80 | Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer. ( Bi, F; Cao, D; Chen, Y; Gou, HF; Li, Q; Li, ZP; Liu, JY; Peng, XC; Qiu, M; Shen, YL; Wang, X; Xu, F; Yang, Y; Yi, C; Zhao, YQ, 2015) |
| "Our study indicates that S-1 monotherapy is safe and well tolerated in chemotherapy-naïve elderly patients with AGC, but exerts limited activity when given using a tailor-made dosing strategy based on renal function." | 2.79 | Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). ( Furukawa, H; Iijima, S; Imamura, H; Imano, M; Kimura, Y; Kishimoto, T; Kurokawa, Y; Maruyama, K; Morimoto, T; Otsuji, T; Takiuchi, H; Yamashita, K, 2014) |
| "As first-line treatment for advanced gastric cancer, docetaxel plus S-1 significantly improves median overall and progression-free survival as compared with S-1 alone." | 2.79 | Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). ( Cho, JY; Chung, HC; Fujii, M; Hara, T; Hosaka, H; Imamura, H; Inokuchi, M; Kim, HK; Kim, YH; Koizumi, W; Lee, KH; Nakajima, T; Ogura, M; Okuno, T; Satoh, T; Takagane, A; Takeuchi, M; Tanabe, K; Tsuji, A; Yoshida, K, 2014) |
| "Pancreatic cancer is one of the most aggressive cancers with a median survival time (MST) of <6 months in chemotherapy-resistant patients." | 2.78 | A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients. ( Ishihara, Y; Itoh, K; Komatsu, N; Matsueda, S; Mine, T; Noguchi, M; Sasada, T; Yamada, A; Yonemoto, K; Yoshitomi, M; Yutani, S, 2013) |
| "Peritoneal metastasis is treated more effectively by this regimen than other forms of metastases." | 2.78 | Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor. ( Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y, 2013) |
| "Patients with advanced/recurrent gastric cancer were randomized to receive tailored irinotecan and S-1 (arm A) therapy or S-1 therapy alone (arm B)." | 2.76 | Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). ( Kimura, Y; Kitajima, M; Komatsu, Y; Oda, H; Saji, S; Sakamoto, J; Sakata, Y; Sakurai, J; Tajima, Y; Takahashi, M; Takahashi, Y; Tamura, S; Tatebe, S; Wakasugi, T, 2011) |
| "Patients with hormone-resistant breast cancer are assigned to either TS-1 (40-60 mg twice daily for 28 consecutive days, followed by a 14-day rest period) or standard chemotherapy (docetaxel 60-75 mg/m(2) at 3- or 4-week intervals, paclitaxel 175 mg/m(2) at 3- or 4-week intervals or paclitaxel 80-100 mg/m(2) weekly, followed by a 1-week rest period)." | 2.75 | Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC). ( Hozumi, Y; Masuda, N; Mitsuyama, S; Mukai, H; Murakami, S; Ohashi, Y; Ohmura, T; Takashima, T; Watanabe, T; Yajima, T, 2010) |
| "The survival rate of patients with squamous cell carcinoma of the head and neck was 59." | 2.74 | Outpatient chemotherapy with S-1 for recurrent head and neck cancer. ( Shinden, S; Shiotani, A; Watabe, T; Yamashita, T, 2009) |
| "This phase II study evaluated the toxicity and efficacy of a novel dosing schedule of docetaxel and S-1 as treatment for advanced gastric cancer." | 2.74 | Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. ( Egashira, A; Emi, Y; Kakeji, Y; Maehara, Y; Morita, M; Oki, E; Sadanaga, N; Takahashi, I, 2009) |
| "Paclitaxel was administered intravenously on days 1, 8 and 15, at an initial dose of 40 mg/m(2), stepping up to 70 mg/m(2) in 10-mg/m(2) increment." | 2.74 | Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. ( Fukunari, H; Hatano, T; Hayashi, T; Inada, S; Kawauchi, Y; Nikkuni, K; Nishimura, A; Sato, T; Shimizu, T; Sugita, M; Takahashi, S; Tomidokoro, T; Yanagi, M; Yoshida, H, 2009) |
| "Advanced gastric cancer can respond to S-1, an oral fluoropyrimidine." | 2.73 | Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. ( Arai, K; Fujii, M; Furukawa, H; Higashino, M; Imamura, H; Kinoshita, T; Kurita, A; Nakajima, T; Nashimoto, A; Ohashi, Y; Sakuramoto, S; Sasako, M; Yamaguchi, T; Yamamura, Y, 2007) |
| "Lentinan (LNT) is a beta-glucan known to have a life-prolonging effect in combination with chemotherapy for patients with unresectable or recurrent gastric cancer." | 2.72 | [S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]. ( Kashimura, H; Kashiwagi, H; Mitsumori, N; Nimura, H; Takahashi, N; Takayama, S; Yanaga, K, 2006) |
| "Paclitaxel was given intravenously on days 1, 8, and 15, starting with a dose of 40 mg m-2 day-1." | 2.72 | Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer. ( Aihara, R; Asao, T; Haga, N; Kamiyama, Y; Kuwano, H; Mochiki, E; Nakabayashi, T; Nakamura, J; Ohno, T; Ohsawa, H; Ojima, H; Takeuchi, K, 2006) |
| " With these findings in mind, we recently devised a new dosing regimen for the drug, by which the drug is administered for 2-week periods separated by 1-week drug-free intervals (the 2-week regimen)." | 2.71 | A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. ( Hayashi, T; Iijima, S; Kato, T; Kikkawa, N; Kimura, Y; Kurokawa, E; Naoi, Y; Tanigawa, T; Yamamoto, H, 2003) |
| " A biological response modifier, lentinan (LNT) prolonged the survival period of patients with UARG when combined with tegafur (FT)." | 2.71 | [Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer]. ( Atomi, Y; Kusano, M; Mitsumori, N; Nakajima, M; Nimura, H; Suzuki, S; Tokunaga, A; Tsukagoshi, S; Yoshiyuki, T, 2003) |
| "We designed an outpatient regimen consisting of fractional cisplatin in combination with S-1, a novel oral fluoropyrimidine derivative for the treatment of recurrent or advanced gastric cancer and conducted a phase I study to determine the dose limiting toxicities (DLTs) and recommended dose (RD)." | 2.71 | Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study. ( Hiki, N; Imamura, K; Kaminishi, M; Mafune, K; Shimoyama, S; Yamaguchi, H, 2005) |
| "Paclitaxel was infused over 1 h on days 1, 8, and 15." | 2.71 | Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. ( Ichikawa, D; Kakihara, N; Koizumi, K; Kurioka, H; Morii, J; Morita, S; Nakamura, K; Nishiyama, M; Sakamoto, J; Shimotsuma, M; Takenaka, A; Ueda, Y; Yamagishi, H; Yamashita, T, 2005) |
| "TS-1 is a promising drug for gastric cancer with peritoneal dissemination." | 2.70 | [The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002) |
| "There was no gastric cancer progression." | 2.48 | Hypomanic episode during recurrent gastric cancer treatment: report of a rare case and literature review. ( Araki, K; Ishida, M; Kaneta, T; Matsunaga, M; Miwa, K; Nakayama, H; Narabayashi, M; Noguchi, T; Onishi, H; Sasaki, Y; Shimada, K; Sunakawa, Y, 2012) |
| " The main adverse events (AEs) of anlotinib combined with S-1 were fatigue (58." | 1.62 | Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy. ( Cai, J; Liu, A; Luo, Y; Zhou, S, 2021) |
| "Hereby, we report a case of type 4 gastric cancer with peritoneal dissemination successfully treated with conversion surgery after intensive SOX chemotherapy." | 1.62 | [A Case of Type 4 Gastric Cancer with Peritoneal Dissemination Successfully Treated with Conversion Surgery after Intensive S-1 plus Oxaliplatin Chemotherapy]. ( Iwasaki, K; Kitamura, K; Koide, N; Koyama, M; Matsumura, T; Nomori, H; Obana, A; Sato, Y; Suwa, T; Usui, S; Yoshida, R, 2021) |
| "The Japanese Gastric Cancer Treatment Guidelines recommend S-1 and S-1 plus docetaxel as postoperative chemotherapy for pathological stage II and III gastric cancer (GC)." | 1.62 | Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study. ( Arigami, T; Kurahara, H; Matsushita, D; Mori, S; Noda, M; Ohtsuka, T; Okubo, K; Sasaki, K; Tanaka, T; Tsuruda, Y, 2021) |
| "Lymph node metastasis was an independent risk factor for both locoregional (P < 0." | 1.62 | Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma. ( Hayami, S; Hirono, S; Kawai, M; Kitahata, Y; Kobayashi, R; Miyazawa, M; Okada, KI; Ueno, M; Yamaue, H, 2021) |
| " Thirty-two patients developed 54 events of CRT-related adverse events, including only one patient with a grade 3 event (stomatitis)." | 1.62 | Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer. ( Doki, Y; Eguchi, H; Kitakaze, M; Miyoshi, N; Mizushima, T; Murata, K; Noura, S; Ohue, M; Takahashi, H; Tei, M; Uemura, M, 2021) |
| " Although weekly paclitaxel followed by reduced S-1 dosage was introduced after surgery, the recurrent mass was observed in the para-aortic region after 2 years." | 1.56 | [A Case of Long-Term Survival with Far Advanced Gastric Cancer after Multidisciplinary Treatments, including Conversion Surgery]. ( Akiyama, T; Fujiwara, Y; Higashida, M; Iwamoto, R; Kinoshita, S; Kitagawa, S; Kubota, H; Mineta, S; Okada, T; Okamoto, Y; Tsuruta, A; Ueno, M; Ueno, T; Watanabe, Y, 2020) |
| "A large proportion of recurrent cervical cancer (RCC) patients present with poor performance status (PS) after comprehensive treatments, which usually prevents them from opting for clinical trials." | 1.56 | Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series. ( Jiang, SN; Shang, YP; Wang, ZM; Xu, XJ, 2020) |
| "Forced expression of CDO1 in gastric cancer cell lines was assessed using the JC-1 assay." | 1.56 | Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer. ( Harada, H; Hiki, N; Hosoda, K; Nishizawa, N; Soeno, T; Ushiku, H; Yamashita, K; Yokoi, K, 2020) |
| "Some postoperative gastric cancer patients have to terminate systemic intravenous chemotherapy early due to adverse drug reactions." | 1.51 | The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients. ( Cao, T; Han, X; Li, G; Li, H; Liu, H; Wang, C; Yan, L, 2019) |
| "We report a case of advanced gastric cancer with stenosis under severe malnutrition, in which nutritional treatment along with chemotherapy using an elemental diet(ED)tube led to complete resection of the tumor." | 1.51 | [A Case of Curative Resection of Locally Advanced Gastric Cancer after Nutrition Therapy and Chemotherapy with S-1 and Oxaliplatin Using Elemental Diet Tube]. ( Deguchi, S; Hirakawa, K; Hori, T; Ishikawa, T; Masuda, G; Nakata, B; Sakimura, C; Tani, N; Tendo, M, 2019) |
| "A 60s man was diagnosed with rectal cancer and underwent low anterior resection of the rectum." | 1.51 | [A Case of Curatively Resected Locally Recurrent Rectal Mucinous Adenocarcinoma Followed by Preoperative Chemoradiotherapy]. ( Ishida, T; Kajiwara, T; Kamei, T; Karasawa, H; Kohyama, A; Naitoh, T; Ohnuma, S; Sato, K; Suzuki, H; Unno, M; Watanabe, K, 2019) |
| "A-67-year old man was diagnosed with gastric cancer and a liver tumor." | 1.51 | [A Case of Gastric Endocrine Carcinoma with a Huge Liver Metastasis]. ( Kawaoka, T; Kubo, H; Miyahara, M; Nabeya, M; Nishida, Y; Saeki, S; Sasaki, S; Tamesa, T; Tokunou, K; Yamamoto, S; Yamashita, Y, 2019) |
| "We report a case of advanced gastric cancer with right gastroepiploic vein tumor thrombus treated using preoperative S-1 plus cisplatin(CDDP)in which pathological complete response was achieved." | 1.51 | [A Case of Advanced Gastric Cancer with Right Gastroepiploic Vein Tumor Thrombus Treated by Preoperative S-1 plus CDDP That Resulted in Pathological Complete Response]. ( Arai, S; Goseki, N; Koike, M; Kuwabara, H; Nakamura, N; Sanada, T; Sato, T; Tomi, Y; Yoshida, T, 2019) |
| "Although the prognosis ofypStage Ⅰgastric cancer was comparatively good, the regimen and courses ofpostoperative chemotherapy should be evaluated in a prospective study." | 1.51 | [Adjuvant Chemotherapy and the Prognosis of ypStageⅠ Gastric Cancer]. ( Akamaru, Y; Azama, T; Kitada, M; Morimoto, O; Munakata, K; Ota, H; Shibata, K; Takiuchi, D; Wada, N; Wada, R, 2019) |
| "A scirrhous gastric cancer was found, and he was introduced to us." | 1.51 | [Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases]. ( Doki, Y; Kurokawa, Y; Makino, T; Miyazaki, Y; Mori, M; Nakajima, K; Noma, T; Takahashi, T; Tanaka, K; Yamasaki, M, 2019) |
| "We report a case of recurrent gastric cancer that was successfully treated by S-1 chemotherapy." | 1.51 | [A Case of Recurrent Gastric Cancer Successfully Treated by S-1 Chemotherapy]. ( Hata, M; Hoshino, H; Imamoto, H; Kawada, J; Kim, Y; Nagai, K; Nishino, M; Ogino, T; Okano, M; Okuyama, M; Tanizaki, K; Tsujinaka, T, 2019) |
| "Among gastric cancer patients who underwent curative gastrectomy followed by adjuvant S-1 monotherapy, patients who experienced a recurrence while receiving adjuvant therapy or within 6 months after completion and started systemic chemotherapy at four institutions between 2005 and 2015 were eligible." | 1.51 | Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study. ( Chin, K; Hara, H; Hasegawa, H; Hirao, M; Kadowaki, S; Mitani, S; Muro, K; Nishikawa, K; Tajika, M; Takahari, D; Wakatsuki, T, 2019) |
| "She was diagnosed with clinical Stage Ⅳ gastric cancer(cT3N2M1H1)." | 1.51 | [A Case of Advanced Gastric Cancer with Pathological Complete Response after Chemotherapy(S-1/Cisplatin)]. ( Egawa, H; Fukunaga, T; Ishibashi, Y; Kaji, S; Kajiyama, Y; Kanda, S; Kohira, Y; Oka, S; Sakamoto, K; Yube, Y, 2019) |
| "Although, gastric cancer is one of the most common cancers worldwide, alpha-fetoprotein (AFP) producing human epidermal growth factor receptor 2 (HER2) positive gastric cancers are rare." | 1.48 | Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2. ( Arakawa, Y; Hayashi, K; Nagasaki, E; Nakada, K; Tamura, M; Uwagawa, T; Yano, S, 2018) |
| "However, severe neutropenia is often observed (40%) during this therapy." | 1.48 | Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer. ( Kawachi, S; Kimura, M; Shinoda, Y; Usami, E; Yoshimura, T, 2018) |
| "In the latest Japanese gastric cancer treatment guidelines, PAM plus paclitaxel(PTX)was positioned as a second-line chemotherapy for advanced gastric cancer." | 1.48 | [A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel]. ( Akaishi, T; Hakamada, K; Hara, Y; Kubo, N; Mitsuhashi, Y; Muroya, T; Ogasawara, H; Sato, K; Umemura, K; Umetsu, S; Wajima, N; Wakasa, Y; Yoshida, E; Yoshida, T, 2018) |
| "Dissemination of gastric cancer tends to be difficult to treat and has a poor prognosis." | 1.48 | [Two Cases of Surgical Treatment for Disseminated Gastric Carcinoma]. ( Ajioka, Y; Alexey, A; Aoki, M; Fukunari, H; Hayashi, T; Kawai, Y; Saito, T; Shitara, K; Umebayashi, Y; Watanabe, A, 2018) |
| " The patient received gamma knife stereotactic radiosurgery (GKSRS) combined with S-1 treatment." | 1.46 | Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report. ( Dong, X; Du, F; Tang, S; Wei, H; Wei, J, 2017) |
| "Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed." | 1.46 | Usefulness of chemoradiotherapy for inoperable gastric cancer. ( Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K, 2017) |
| "The prognosis of advanced gastric cancer was significantly related to the start of S-1 adjuvant treatment within 6 weeks after surgery." | 1.43 | S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer. ( Egashira, A; Ikeda, Y; Kinjo, N; Minami, K; Morita, M; Okamura, T; Sakaguchi, Y; Toh, Y; Yamaguchi, S; Yamamoto, M, 2016) |
| "Patients with stage III gastric cancer who underwent D2 gastrectomy were enrolled." | 1.40 | Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer. ( Fuse, N; Goto, M; Hamaguchi, T; Ito, S; Katai, H; Konishi, M; Sano, T; Sasako, M; Shirao, K; Takahari, D; Tanigawa, N; Terashima, M; Yasui, H; Yoshimura, K, 2014) |
| "Management of peritoneal disseminated gastric cancer (GC) remains a challenging problem." | 1.40 | Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan. ( Canbay, E; Hirano, M; Ichinose, M; Ishibashi, H; Mizumoto, A; Sako, S; Takao, N; Yonemura, Y, 2014) |
| "The optimal radiotherapy technique and combination with systemic therapy in locally advanced gastric cancer patients are far from being resolved despite the fact that radiochemotherapy is becoming more attractive in contemporary clinical practice." | 1.40 | Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients. ( Gu, BX; Hu, JB; Hu, WX; Sun, XN; Wang, Q, 2014) |
| " Most adverse events were mild." | 1.40 | Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis. ( Chen, ZB; Cheng, H; Lin, Z; Liu, YM; Ou, XQ; Peng, PJ; Tang, YN; Wang, SY; Wu, X; Zeng, LJ; Zhang, HY, 2014) |
| "The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009." | 1.40 | Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014) |
| "The standard treatment for stage IV gastric cancer is chemotherapy, but outcomes remain poor." | 1.40 | Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients. ( Kiyozaki, H; Rikiyama, T; Saito, M; Suzuki, K; Takata, O, 2014) |
| "Because we suspected septic pulmonary embolism related to the venous port, we removed the venous port promptly and administered antibiotics with a broad spectrum." | 1.39 | [A case of a septic pulmonary embolism-related implanted central venous port]. ( Daga, H; Miyamoto, N; Nishijima, M; Okada, H; Sumitani, M; Syoji, S; Taira, K; Takeda, K; Tokunaga, S; Tsuda, M, 2013) |
| "It may be useful for esophageal squamous cell carcinoma (ESCC); however, there are insufficient data." | 1.39 | S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma. ( Akutsu, Y; Hanaoka, T; Hoshino, I; Kono, T; Matsubara, H; Narushima, K; Qin, W; Semba, Y; Tochigi, T; Uesato, M, 2013) |
| " Pharmacists should consider reducing the treatment dosage and providing nutritional support in such cases." | 1.39 | Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer. ( Kaneoka, Y; Kimura, M; Sugiyama, T; Teramachi, H; Tsuchiya, T; Usami, E; Yasuda, T; Yoshimura, T, 2013) |
| "In resectable advanced laryngeal cancer, S-1 adjuvant chemotherapy is an effective and feasible treatment option to control distant metastases following reduced RADPLAT." | 1.38 | Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer. ( Endo, K; Kondo, S; Murono, S; Wakisaka, N; Yoshizaki, T, 2012) |
| "In patients with stage II/III gastric cancer, tumors often recur even after curative D2 gastrectomy followed by adjuvant S-1 chemotherapy." | 1.37 | Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1. ( Aoyama, T; Cho, H; Hayashi, T; Ogata, T; Tsuburaya, A; Watanabe, T; Yoshikawa, T, 2011) |
| "Gluteal recurrence of the original gastric cancer was suggested, and systemic chemotherapy consisting of S-1 at 100 mg/day (3 weeks on, 1 week off) and CDDP (day 8) was started." | 1.37 | Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination. ( Deguchi, R; Iwata, Y; Mine, T; Numata, M; Ogasawara, F; Ohtani, Y; Sakuma, T; Sato, S; Takashimizu, S, 2011) |
| "S-1 is an oral anticancer drug containing tegafur (FT), a pro-drug of fluorouracil, combined with two modulators, 5-chloro-2,4-dihydroxypyridine and potassium oxonate (Oxo), at a molar ratio of 1:0." | 1.36 | Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1? ( Asai, S; Ishii, Y; Suzuki, S; Takahashi, Y; Takayama, T, 2010) |
| "Paclitaxel 50mg/m2 was administered on days 1 and 8." | 1.36 | [Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)]. ( Fujitani, K; Furukawa, H; Kimura, Y; Machida, H; Shimokawa, T; Takiuchi, H; Tominaga, K; Tsujinaka, T; Yamamoto, M; Yano, H, 2010) |
| "The treatment for hepatocellular carcinoma with distant metastasis remains unclear." | 1.36 | [A successful case of S-1 chemotherapy for bilateral pulmonary recurrence of hepatocellular carcinoma long after hepatectomy]. ( Fukumori, D; Kamachi, H; Kamiyama, T; Matsushita, M; Nakanishi, K; Tahara, M; Todo, S; Yokoo, H, 2010) |
| "Patients with residual tumors after the initial treatment had a response rate of 47." | 1.36 | [Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment]. ( Katsuno, M; Sato, N; Sugio, Y; Tachibana, S; Tani, Y; Watanabe, N; Zusho, H, 2010) |
| "Lymph node metastasis was confirmed." | 1.36 | [A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin]. ( Endo, W; Fujie, Y; Fukunaga, H; Hojou, S; Maeura, Y; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S, 2010) |
| "We report a case of local recurrent colorectal cancer that has been treated successfully with low-dose oral chemotherapeutic agent." | 1.36 | [A case of local relapsed rectal cancer responding to low-dose S-1]. ( Fujita, S; Ikeda, N; Kanamura, T; Kojima, Y; Nakagawa, K; Ueno, M, 2010) |
| "To cure intrahepatic cholangiocarcinoma (ICC), only a surgical resection is the potential treatment at present." | 1.36 | [A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection]. ( Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Nagano, H; Takeda, Y; Tanemura, M; Tanida, T; Umeshita, H; Wada, H, 2010) |
| "A 65-year-old man with common bile duct cancer was treated by pylorus-preserving pancreaticoduodenectomy with D2 lymph node dissection." | 1.35 | [A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy]. ( Fukao, K; Irabu, S; Kasagawa, T; Kusashio, K; Matsumoto, M; Nobumoto, D; Suzuki, M; Tashima, Y; Tonooka, T; Udagawa, I; Yasutomi, J, 2008) |
| "A type 2 advanced gastric cancer was observed on the gastric antrum." | 1.35 | [A case of early recurrence with multiple liver metastases after curative operation of gastric cancer successfully treated by S-1/CDDP combination chemotherapy]. ( Akiho, H; Goto, A; Itaba, S; Murao, H; Nagai, E; Nakamura, K; Segawa, Y; Takayanagi, R; Tokunaga, N; Yoshinaga, S, 2008) |
| " Five patients showed grade 3 and 4 adverse reactions, all hematological." | 1.35 | Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. ( Ishikawa, K; Suzuki, S, 2009) |
| " It is also considered necessary to adjust the dosage of the anticancer drugs and the dosing period for patients with a PS of 2 when preparing a chemotherapeutic regimen for digestive carcinoma, including stomach carcinoma." | 1.35 | [Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer]. ( Akasaka, O; Anan, H; Ando, T; Iwase, S; Kasama, M; Koh, R; Matsueda, R; Miwa, H; Morita, S, 2009) |
| "We describe a case of locally recurrent rectal cancer that was successfully treated with radiation and chemotherapy with S-1; this treatment resulted in long-term survival of the patient with a good performance status." | 1.35 | [A case of locally recurrent rectal cancer responding to radiation and chemotherapy with S-1]. ( Baba, H; Fujiwara, N; Goseki, N; Kuwabara, H; Nakajima, K; Nakamura, H; Tamai, S, 2009) |
| " He was treated with single agent S-1 in 10 courses on a 4-week dosing regimen with a 2-week interval." | 1.35 | [A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy]. ( Iwanaga, T; Iwasaki, Y; Matsumoto, H; Matsumura, H; Nakano, D; Ohashi, M; Takahashi, K; Yamaguchi, T, 2009) |
| "But second primary gastric cancer was detected in antrum 26 months after primary therapy." | 1.35 | [A case of advanced gastric cancer treated with S-1 and S-1/paclitaxel showing complete response twice]. ( Fukushima, Y; Hashimoto, K; Hiraki, M; Matsumoto, S; Matsuyama, J; Morimoto, T; Morita, S; Naitou, A; Nishishou, I; Nomura, T; Sasaki, Y; Yokoyama, S, 2009) |
| " But, we dosed down with S-1 due to severe diarrhea." | 1.35 | [A case of successful control of recurrent duodenal carcinoma receiving paclitaxel]. ( Akitake, H; Ebisui, C; Fujimoto, T; Hama, N; Kashiwazaki, M; Konishi, M; Maekawa, T; Ookubo, K; Ootsuka, M; Taniguchi, M; Tsujie, M; Yoshioka, S, 2009) |
| "Recently, chemotherapy against gastric cancer has been diversified with an appearance of new agents such as S-1, capecitabine, CPT-11, oxaliplatin, paclitaxel and docetaxel." | 1.35 | [A case of recurrence gastric cancer patient who was post operated and multi drug chemotherapy was effective for administration of S-1 and docetaxel combination therapy]. ( Ami, K; Andou, M; Arai, K; Fukuda, A; Ganno, H; Hataji, K; Kurokawa, T; Nagahama, T; Ohara, T; Tei, S, 2009) |
| "An 82-year-old female with unresectable colon cancer accompanied by multiple lung metastasis was treated with S-1." | 1.35 | [An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response]. ( Arita, A; Fujimoto, M; Mochizuki, K; Sakai, Y, 2008) |
| "Current therapy for advanced pancreatic cancer focuses largely on gemcitabine." | 1.35 | Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer. ( Alsamarai, S; Furuie, T; Saif, MW; Urrea, PD; Zergebel, C; Zhang, J, 2008) |
| " This article identifies the risk factors for severe adverse events of S-1 from nationwide survey data." | 1.34 | Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. ( Fukushima, M; Ishiwata, R; Matsumoto, S; Nagai, Y; Teramukai, S; Yamanaka, T, 2007) |
| " The patient was treated with S-1 combined with CPT-11." | 1.34 | [An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11]. ( Doi, M; Egawa, T; Hayashi, S; Ito, Y; Kitano, M; Nagashima, A; Sekine, K; Shimizu, M; Yoshii, H, 2007) |
| "A 58-year-old man with gastric cancer who had undergone distal gastrectomy on February 8, 2001 was revealed to have anorexia, and was diagnosed with a local recurrence in anastomosis by upper GI examination in August 2003." | 1.33 | [Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report]. ( Fujii, M; Kasakura, Y; Kochi, M; Morishita, Y; Sato, K; Takayama, T; Yamagata, M, 2005) |
| " There were less severe adverse events concerning paclitaxel despite of the second line therapy of TS-1, and 80 percent of all therapeutic courses was at an outpatient clinic." | 1.33 | [Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination]. ( Banba, T; Hatakeyama, K; Kanda, T; Kosugi, S; Ohashi, M; Tanabe, T; Yajima, K, 2005) |
| "The patient diagnosed as recurrent pancreatic cancer was treated with UFT combined gemcitabine (GEM) chemotherapy." | 1.33 | [A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease]. ( Kagaya, T; Kaneko, S; Kato, Y; Sunagozaka, H; Yamashita, T, 2006) |
| " We carried out 4-week administration of 80-120 mg/day of TS-1 according to body surface area, followed by a 2-week discontinuation, then repeated administration which adjusting the dosage according to the incidence of side effects, and discussed the antitumor effects and adverse events." | 1.33 | [Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer]. ( Hatori, S; Imada, T; Kunisaki, C; Makino, T; Ohshima, T; Rino, Y; Suda, T; Takanashi, Y; Yamada, R; Yamazaki, Y, 2006) |
| " The adverse effects observed were grade 3 leukopenia in 2 patients (11." | 1.33 | [Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy]. ( Hatori, S; Imada, T; Kunisaki, C; Ohshima, T; Ono, H; Otsuka, Y; Rino, Y; Sato, T; Yamada, R, 2006) |
| "We treated a recurrent gastric cancer patient with chronic renal failure who developed grade 2 HFS, grade 2 conjunctivitis and grade 3 stomatitis soon after TS-1 administration." | 1.32 | [A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome]. ( Arai, K; Honma, S; Iwasaki, Y; Kimura, Y; Takahashi, K; Takahashi, T; Yamaguchi, T, 2003) |
| " TS-1 was administered with the usual dosage and dose regimen." | 1.32 | [A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital]. ( Abe, S; Kitago, M; Kobayashi, T; Kojima, M; Kurihara, H; Nakamura, T; Ogihara, T; Tamura, H, 2003) |
| "Although the prognosis of recurrent gastric cancer with peritoneal dissemination was extremely poor, this case might suggest a possibility that intensive therapies are useful in maintaining the quality of life and improving survival." | 1.32 | [A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy]. ( Ebisui, C; Fujimoto, T; Fukuchi, N; Hasuike, Y; Hayashi, N; Izawa, H; Sakita, I; Souma, I; Yoshida, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.32) | 18.2507 |
| 2000's | 96 (30.87) | 29.6817 |
| 2010's | 177 (56.91) | 24.3611 |
| 2020's | 37 (11.90) | 2.80 |
| Authors | Studies |
|---|---|
| Hosoda, K | 3 |
| Fukushima, K | 1 |
| Shimizu, A | 1 |
| Motoyama, H | 1 |
| Kubota, K | 4 |
| Notake, T | 1 |
| Sugenoya, S | 1 |
| Hayashi, H | 2 |
| Yasukawa, K | 1 |
| Kobayashi, R | 4 |
| Soejima, Y | 1 |
| Mei, Y | 1 |
| Shi, M | 1 |
| Zhu, Z | 2 |
| Yuan, H | 1 |
| Yan, C | 1 |
| Li, C | 1 |
| Feng, T | 1 |
| Yan, M | 1 |
| Zhang, J | 2 |
| Miyajima, N | 1 |
| Ragab Eissa, I | 1 |
| Abdelmoneim, M | 1 |
| Naoe, Y | 1 |
| Ichinose, T | 1 |
| Matsumura, S | 1 |
| Bustos-Villalobos, I | 1 |
| Mukoyama, N | 1 |
| Morimoto, D | 1 |
| Shibata, M | 1 |
| Takeuchi, D | 1 |
| Tsunoda, N | 1 |
| Kikumori, T | 1 |
| Tanaka, M | 2 |
| Kodera, Y | 5 |
| Kasuya, H | 1 |
| Cai, J | 1 |
| Zhou, S | 1 |
| Luo, Y | 1 |
| Liu, A | 1 |
| Soeno, T | 2 |
| Katoh, H | 1 |
| Ishii, S | 1 |
| Ushiku, H | 3 |
| Hiki, N | 6 |
| Watanabe, M | 3 |
| Yamashita, K | 3 |
| Yamaguchi, T | 9 |
| Takashima, A | 2 |
| Nagashima, K | 1 |
| Makuuchi, R | 1 |
| Aizawa, M | 1 |
| Ohashi, M | 7 |
| Tashiro, K | 1 |
| Yamada, T | 2 |
| Kinoshita, T | 2 |
| Hata, H | 2 |
| Kawachi, Y | 1 |
| Kawabata, R | 1 |
| Tsuji, T | 2 |
| Hihara, J | 6 |
| Sakamoto, T | 2 |
| Fukagawa, T | 1 |
| Katai, H | 3 |
| Higuchi, K | 2 |
| Boku, N | 11 |
| Liao, W | 1 |
| Huang, J | 3 |
| Zhu, G | 1 |
| Zhou, J | 1 |
| Wen, F | 1 |
| Zhang, P | 1 |
| Zhou, K | 1 |
| Wu, Q | 1 |
| Wang, X | 4 |
| Gou, H | 1 |
| Li, Q | 3 |
| Fujimoto, H | 1 |
| Ito, S | 4 |
| Kawaguchi, K | 2 |
| Isobe, H | 1 |
| Urayama, M | 1 |
| Fuse, A | 1 |
| Ota, K | 1 |
| Yan, L | 1 |
| Liu, H | 1 |
| Li, H | 1 |
| Han, X | 1 |
| Cao, T | 1 |
| Wang, C | 1 |
| Li, G | 1 |
| Kudo, R | 1 |
| Manaka, D | 1 |
| Ikeda, Y | 3 |
| Ota, T | 1 |
| Hamasu, S | 1 |
| Konishi, S | 1 |
| Nishitai, R | 1 |
| Yang, PC | 1 |
| Huang, KW | 1 |
| Pua, U | 1 |
| Kim, MD | 1 |
| Li, SP | 1 |
| Li, XY | 1 |
| Liang, PC | 1 |
| Shimizu, T | 2 |
| Ishizuka, M | 1 |
| Sakuraoka, Y | 1 |
| Shiraki, T | 1 |
| Abe, A | 1 |
| Mori, S | 2 |
| Iso, Y | 1 |
| Takagi, K | 1 |
| Aoki, T | 3 |
| Jiang, Z | 1 |
| Sun, Y | 1 |
| Zhang, W | 1 |
| Cui, C | 1 |
| Yang, L | 2 |
| Zhou, A | 1 |
| Nishibeppu, K | 1 |
| Komatsu, S | 1 |
| Imamura, T | 1 |
| Kiuchi, J | 1 |
| Kishimoto, T | 2 |
| Arita, T | 1 |
| Kosuga, T | 1 |
| Konishi, H | 2 |
| Kubota, T | 3 |
| Shiozaki, A | 1 |
| Fujiwara, H | 1 |
| Okamoto, K | 2 |
| Otsuji, E | 2 |
| Watanabe, H | 1 |
| Hayashi, T | 10 |
| Komori, K | 1 |
| Hara, K | 2 |
| Maezawa, Y | 1 |
| Kano, K | 1 |
| Shimoda, Y | 2 |
| Fujikawa, H | 1 |
| Aoyama, T | 4 |
| Yamamoto, N | 3 |
| Cho, H | 7 |
| Ito, H | 1 |
| Shiozawa, M | 1 |
| Yukawa, N | 1 |
| Morinaga, S | 1 |
| Yoshikawa, T | 4 |
| Rino, Y | 3 |
| Masuda, M | 1 |
| Ogata, T | 4 |
| Oshima, T | 3 |
| Urahigashi, A | 1 |
| Fukunaga, H | 2 |
| Sawami, H | 1 |
| Hiraki, M | 2 |
| Sawada, G | 1 |
| Murakami, M | 4 |
| Chihara, Y | 1 |
| Yamamoto, M | 4 |
| Kimura, H | 1 |
| Morita, S | 15 |
| Hokkoku, D | 2 |
| Akamaru, Y | 3 |
| Wada, N | 3 |
| Wada, R | 3 |
| Ikeshima, R | 2 |
| Munakata, K | 3 |
| Takiuchi, D | 3 |
| Morimoto, O | 3 |
| Ota, H | 7 |
| Shibata, K | 3 |
| Ohash, H | 1 |
| Ando, K | 1 |
| Tomimaru, Y | 2 |
| Iwazawa, T | 1 |
| Noguchi, K | 2 |
| Nagase, H | 2 |
| Ogino, T | 3 |
| Hirota, M | 2 |
| Oshima, K | 1 |
| Tanida, T | 3 |
| Noura, S | 2 |
| Kawase, T | 2 |
| Imamura, H | 9 |
| Akagi, K | 1 |
| Dono, K | 5 |
| Deguchi, S | 1 |
| Tendo, M | 1 |
| Tani, N | 1 |
| Sakimura, C | 1 |
| Masuda, G | 1 |
| Hori, T | 1 |
| Nakata, B | 6 |
| Ishikawa, T | 3 |
| Hirakawa, K | 7 |
| Sato, K | 4 |
| Karasawa, H | 1 |
| Kajiwara, T | 1 |
| Suzuki, H | 2 |
| Kohyama, A | 1 |
| Watanabe, K | 2 |
| Ohnuma, S | 1 |
| Ishida, T | 1 |
| Kamei, T | 2 |
| Naitoh, T | 3 |
| Unno, M | 4 |
| Hayashi, Y | 1 |
| Matsuo, Y | 2 |
| Hamano, S | 1 |
| Oba, A | 1 |
| Ueda, G | 1 |
| Omi, K | 1 |
| Imafuji, H | 1 |
| Saito, K | 1 |
| Tsuboi, K | 1 |
| Morimoto, M | 1 |
| Ogawa, R | 1 |
| Takahashi, H | 3 |
| Takiguchi, S | 4 |
| Kataoka, N | 1 |
| Hiramatsu, S | 1 |
| Yasuda, K | 1 |
| Kashu, N | 1 |
| Yoshitake, H | 1 |
| Takami, T | 1 |
| Tomita, M | 1 |
| Shono, Y | 1 |
| Makimoto, S | 1 |
| Chuman, M | 1 |
| Takahashi, Y | 6 |
| Tokito, T | 1 |
| Chino, S | 1 |
| Ema, A | 1 |
| Nakamura, K | 4 |
| Kubo, H | 2 |
| Naito, M | 1 |
| Kondo, Y | 1 |
| Nishi, Y | 1 |
| Tamesa, T | 1 |
| Saeki, S | 2 |
| Nishida, Y | 1 |
| Nabeya, M | 1 |
| Tokunou, K | 1 |
| Kawaoka, T | 1 |
| Miyahara, M | 1 |
| Sasaki, S | 1 |
| Yamashita, Y | 2 |
| Yamamoto, S | 3 |
| Sato, T | 4 |
| Nakamura, N | 1 |
| Arai, S | 1 |
| Tomi, Y | 1 |
| Sanada, T | 1 |
| Kuwabara, H | 3 |
| Yoshida, T | 4 |
| Goseki, N | 2 |
| Koike, M | 2 |
| Yoshida, R | 2 |
| Nagata, M | 1 |
| Hirosue, A | 1 |
| Kawahara, K | 1 |
| Nakamoto, M | 1 |
| Hirayama, M | 1 |
| Takahashi, N | 2 |
| Matsuoka, Y | 1 |
| Sakata, J | 1 |
| Nakashima, H | 1 |
| Arita, H | 1 |
| Hiraki, A | 1 |
| Shinohara, M | 1 |
| Kikuchi, K | 1 |
| Nakayama, H | 3 |
| Kinoshita, S | 1 |
| Higashida, M | 1 |
| Kubota, H | 2 |
| Kitagawa, S | 1 |
| Iwamoto, R | 1 |
| Ueno, M | 3 |
| Mineta, S | 1 |
| Okamoto, Y | 1 |
| Watanabe, Y | 2 |
| Okada, T | 3 |
| Tsuruta, A | 1 |
| Akiyama, T | 1 |
| Fujiwara, Y | 6 |
| Ueno, T | 1 |
| Kobayashi, T | 2 |
| Mizuno, S | 1 |
| Matsuba, H | 1 |
| Kanamori, M | 1 |
| Maruyama, S | 1 |
| Tamauchi, T | 1 |
| Tohyama, T | 1 |
| Sakamoto, K | 3 |
| Tamura, K | 2 |
| Nakamura, T | 3 |
| Watanabe, J | 1 |
| Wakisaka, H | 1 |
| Takada, Y | 1 |
| Ogawa, K | 2 |
| Honda, M | 1 |
| Akashi, Y | 1 |
| Inagawa, S | 1 |
| Kaneda, A | 1 |
| Hori, S | 1 |
| Owada, Y | 1 |
| Ohara, Y | 1 |
| Hisakura, K | 1 |
| Enomoto, T | 1 |
| Shimomura, O | 1 |
| Takahashi, K | 8 |
| Oda, T | 1 |
| Xu, XJ | 1 |
| Wang, ZM | 1 |
| Shang, YP | 1 |
| Jiang, SN | 1 |
| Harada, H | 2 |
| Yokoi, K | 1 |
| Nishizawa, N | 1 |
| Naruse, T | 1 |
| Hirono, Y | 1 |
| Kurebayashi, H | 1 |
| Katayama, H | 1 |
| Sawai, K | 1 |
| Morikawa, M | 1 |
| Koneri, K | 1 |
| Tamaki, M | 1 |
| Goi, T | 1 |
| Kang, M | 1 |
| Youn, HG | 1 |
| An, JY | 2 |
| Choi, MG | 2 |
| Lee, JH | 2 |
| Sohn, TS | 3 |
| Bae, JM | 2 |
| Kim, S | 3 |
| Shimokawa, T | 4 |
| Yamada, K | 1 |
| Tanaka, H | 5 |
| Takiguchi, Y | 2 |
| Kishi, K | 2 |
| Saito, H | 1 |
| Hosomi, Y | 1 |
| Kato, T | 4 |
| Harada, D | 1 |
| Otani, S | 1 |
| Kasai, T | 1 |
| Nakamura, Y | 3 |
| Misumi, T | 2 |
| Yamanaka, T | 4 |
| Okamoto, H | 2 |
| Obana, A | 1 |
| Usui, S | 1 |
| Koyama, M | 2 |
| Koide, N | 1 |
| Iwasaki, K | 1 |
| Matsumura, T | 1 |
| Sato, Y | 3 |
| Kitamura, K | 2 |
| Nomori, H | 1 |
| Suwa, T | 1 |
| Yamakoshi, Y | 1 |
| Ohtani, H | 1 |
| Nagamori, M | 1 |
| Nomura, S | 1 |
| Nakagawa, H | 1 |
| Yoshii, M | 1 |
| Tamura, T | 3 |
| Toyokawa, T | 2 |
| Muguruma, K | 3 |
| Ohira, M | 3 |
| Eguchi, S | 1 |
| Noro, H | 1 |
| Hirao, T | 1 |
| Takayama, K | 1 |
| Hara, S | 1 |
| Yoshida, M | 1 |
| Yoneda, K | 1 |
| Ohashi, T | 1 |
| Osawa, H | 1 |
| Sakai, K | 1 |
| Ide, Y | 2 |
| Iwasaki, T | 1 |
| Hatanaka, N | 1 |
| Yamasaki, Y | 1 |
| Yoshida, Y | 1 |
| Okubo, K | 1 |
| Arigami, T | 1 |
| Matsushita, D | 1 |
| Tanaka, T | 2 |
| Tsuruda, Y | 1 |
| Noda, M | 1 |
| Sasaki, K | 2 |
| Kurahara, H | 1 |
| Ohtsuka, T | 1 |
| Inoue, H | 3 |
| Todaka, A | 2 |
| Yamazaki, K | 5 |
| Fushiki, K | 1 |
| Shirasu, H | 1 |
| Kawakami, T | 1 |
| Tsushima, T | 3 |
| Hamauchi, S | 2 |
| Yokota, T | 2 |
| Machida, N | 5 |
| Fukutomi, A | 5 |
| Onozawa, Y | 5 |
| Andoh, A | 1 |
| Yasui, H | 7 |
| Morita, R | 1 |
| Sawai, Y | 1 |
| Kajiwara, M | 1 |
| Asaeda, K | 1 |
| Miyazaki, H | 1 |
| Doi, T | 4 |
| Inoue, K | 4 |
| Dohi, O | 1 |
| Yoshida, N | 1 |
| Kamada, K | 1 |
| Uchiyama, K | 1 |
| Takagi, T | 2 |
| Naito, Y | 1 |
| Itoh, Y | 1 |
| Li, B | 1 |
| Shen, S | 1 |
| You, S | 1 |
| Zhang, G | 1 |
| Gao, S | 1 |
| Shi, X | 1 |
| Wang, H | 1 |
| Yin, X | 1 |
| Xu, X | 1 |
| Guo, S | 1 |
| Jin, G | 1 |
| Miki, M | 1 |
| Takao, S | 1 |
| Konishi, M | 4 |
| Shigeoka, Y | 1 |
| Miyashita, M | 1 |
| Suwa, H | 1 |
| Miyoshi, Y | 2 |
| Hirokaga, K | 1 |
| Okuno, T | 3 |
| Yamagami, K | 1 |
| Imamura, M | 1 |
| Murase, K | 1 |
| Yanai, A | 1 |
| Tanino, H | 1 |
| Natsuki, S | 1 |
| Kato, Y | 3 |
| Nishimura, S | 1 |
| Taenaka, N | 2 |
| Hirono, S | 1 |
| Kawai, M | 1 |
| Okada, KI | 1 |
| Miyazawa, M | 1 |
| Kitahata, Y | 1 |
| Hayami, S | 1 |
| Yamaue, H | 1 |
| Tei, M | 1 |
| Ohue, M | 2 |
| Kitakaze, M | 1 |
| Miyoshi, N | 1 |
| Uemura, M | 3 |
| Mizushima, T | 4 |
| Murata, K | 3 |
| Doki, Y | 9 |
| Eguchi, H | 5 |
| Nakazawa, N | 1 |
| Sohda, M | 1 |
| Ide, M | 1 |
| Ubukata, Y | 1 |
| Kuriyama, K | 1 |
| Sano, A | 1 |
| Sakai, M | 1 |
| Yokobori, T | 1 |
| Ogawa, H | 1 |
| Oyama, T | 2 |
| Shirabe, K | 1 |
| Saeki, H | 1 |
| Nishizawa, Y | 1 |
| Haraguchi, N | 1 |
| Kim, H | 2 |
| Nakata, K | 1 |
| Okamura, S | 1 |
| Kudo, T | 2 |
| Satoh, T | 3 |
| Matsuda, C | 2 |
| Nagakawa, Y | 1 |
| Hosokawa, Y | 1 |
| Sahara, Y | 1 |
| Takishita, C | 1 |
| Nakajima, T | 3 |
| Hijikata, Y | 1 |
| Kasuya, K | 1 |
| Katsumata, K | 2 |
| Tokuuye, K | 1 |
| Tsuchida, A | 2 |
| Takayoshi, K | 1 |
| Kusaba, H | 2 |
| Uenomachi, M | 1 |
| Mitsugi, K | 2 |
| Makiyama, C | 1 |
| Makiyama, A | 1 |
| Uchino, K | 1 |
| Shirakawa, T | 1 |
| Shibata, Y | 1 |
| Shinohara, Y | 1 |
| Inadomi, K | 1 |
| Tsuchihashi, K | 1 |
| Arita, S | 1 |
| Ariyama, H | 2 |
| Esaki, T | 5 |
| Akashi, K | 2 |
| Baba, E | 3 |
| Das, K | 1 |
| Taguri, M | 1 |
| Sugimoto, N | 2 |
| Nishikawa, K | 3 |
| Yoshida, K | 11 |
| Tan, P | 1 |
| Tsuburaya, A | 9 |
| Kawahara, T | 1 |
| Shimozuma, K | 1 |
| Shiroiwa, T | 1 |
| Hagiwara, Y | 2 |
| Uemura, Y | 3 |
| Watanabe, T | 5 |
| Taira, N | 1 |
| Fukuda, T | 1 |
| Ohashi, Y | 7 |
| Mukai, H | 2 |
| Hayashi, K | 3 |
| Nagasaki, E | 1 |
| Nakada, K | 1 |
| Tamura, M | 1 |
| Arakawa, Y | 1 |
| Uwagawa, T | 2 |
| Yano, S | 1 |
| Okabayashi, T | 1 |
| Shima, Y | 1 |
| Iwata, J | 1 |
| Sumiyoshi, T | 1 |
| Sui, K | 1 |
| Shimada, Y | 3 |
| Iiyama, T | 1 |
| Zhao, DB | 1 |
| Chi, Y | 1 |
| Tang, Y | 1 |
| Li, N | 1 |
| Wang, SL | 1 |
| Song, YW | 1 |
| Liu, YP | 1 |
| Liu, WY | 1 |
| Ren, H | 1 |
| Zhang, T | 1 |
| Wang, JY | 1 |
| Chen, XS | 1 |
| Fang, H | 1 |
| Wang, WH | 1 |
| Li, YX | 1 |
| Jin, J | 1 |
| Wei, J | 1 |
| Dong, X | 1 |
| Du, F | 1 |
| Tang, S | 1 |
| Wei, H | 1 |
| Kawachi, S | 1 |
| Shinoda, Y | 1 |
| Kimura, M | 5 |
| Usami, E | 2 |
| Yoshimura, T | 3 |
| Kim, SM | 3 |
| Lee, J | 2 |
| Sasako, M | 4 |
| Kano, Y | 2 |
| Takahari, D | 5 |
| Chin, K | 5 |
| Yamaguchi, K | 5 |
| Tsuda, Y | 1 |
| Shoji, Y | 1 |
| Yasufuku, I | 1 |
| Eto, K | 1 |
| Ida, S | 2 |
| Kumagai, K | 2 |
| Nunobe, S | 3 |
| Sano, T | 4 |
| Nakachi, K | 1 |
| Ikeda, M | 3 |
| Shimada, K | 2 |
| Okusaka, T | 2 |
| Saiura, A | 1 |
| Ishii, H | 1 |
| Sugiyama, M | 1 |
| Furuse, J | 1 |
| Sakamoto, H | 1 |
| Shimamura, T | 1 |
| Ohta, T | 1 |
| Yamada, D | 1 |
| Iwagami, Y | 1 |
| Asaoka, T | 1 |
| Noda, T | 2 |
| Kawamoto, K | 2 |
| Gotoh, K | 1 |
| Kobayashi, S | 4 |
| Mori, M | 7 |
| Miki, Y | 1 |
| Kubo, N | 4 |
| Sakurai, K | 1 |
| Aoki, Y | 2 |
| Ochiai, K | 1 |
| Lim, S | 1 |
| Aoki, D | 1 |
| Kamiura, S | 1 |
| Lin, H | 1 |
| Katsumata, N | 2 |
| Cha, SD | 1 |
| Kim, JH | 4 |
| Kim, BG | 1 |
| Hirashima, Y | 1 |
| Fujiwara, K | 1 |
| Kim, YT | 1 |
| Chung, HH | 1 |
| Chang, TC | 1 |
| Kamura, T | 1 |
| Takizawa, K | 1 |
| Takeuchi, M | 3 |
| Kang, SB | 1 |
| Shinkai, M | 2 |
| Imano, M | 4 |
| Chiba, Y | 2 |
| Hiraki, Y | 2 |
| Kato, H | 2 |
| Iwama, M | 2 |
| Shiraisi, O | 1 |
| Yasuda, A | 2 |
| Tsubaki, M | 2 |
| Nishida, S | 2 |
| Kimura, Y | 14 |
| Yasuda, T | 5 |
| Shiraishi, O | 1 |
| Hanibuchi, M | 1 |
| Kakiuchi, S | 1 |
| Atagi, S | 1 |
| Ogushi, F | 1 |
| Shimizu, E | 1 |
| Haku, T | 1 |
| Toyoda, Y | 2 |
| Azuma, M | 3 |
| Kondo, M | 2 |
| Kawano, H | 1 |
| Otsuka, K | 1 |
| Sakaguchi, S | 1 |
| Nokihara, H | 2 |
| Goto, H | 2 |
| Nishioka, Y | 1 |
| Terashima, M | 3 |
| Misawa, K | 1 |
| Hirao, M | 2 |
| Oki, E | 4 |
| Emi, Y | 6 |
| Bando, H | 2 |
| Kawashima, Y | 1 |
| Fukunaga, T | 2 |
| Gotoh, M | 4 |
| Ishibashi, T | 1 |
| Shitara, K | 5 |
| Ryu, MH | 5 |
| Kato, K | 4 |
| Chung, HC | 4 |
| Minashi, K | 2 |
| Lee, KW | 1 |
| Kang, WK | 5 |
| Komatsu, Y | 6 |
| Tsuda, M | 2 |
| Hara, H | 2 |
| Fumita, S | 1 |
| Chen, LT | 1 |
| Kang, YK | 5 |
| Haga, T | 1 |
| Fujimura, T | 2 |
| Aiba, S | 1 |
| Tsuchiya, T | 3 |
| Matsumoto, K | 3 |
| Miyazaki, T | 2 |
| Yamaguchi, H | 3 |
| Yamazaki, T | 1 |
| Sano, I | 1 |
| Fukuoka, J | 2 |
| Yamasaki, N | 2 |
| Nagayasu, T | 2 |
| Muroya, T | 1 |
| Wajima, N | 1 |
| Yoshida, E | 1 |
| Akaishi, T | 1 |
| Umetsu, S | 1 |
| Wakasa, Y | 2 |
| Mitsuhashi, Y | 1 |
| Umemura, K | 1 |
| Ogasawara, H | 1 |
| Hara, Y | 1 |
| Hakamada, K | 2 |
| Suzuki, T | 2 |
| Tazawa, H | 1 |
| Kojima, M | 2 |
| Akabane, S | 1 |
| Hadano, N | 1 |
| Shimizu, W | 1 |
| Ishiyama, K | 1 |
| Onoe, T | 1 |
| Sudo, T | 2 |
| Shimizu, Y | 1 |
| Hinoi, T | 1 |
| Tashiro, H | 2 |
| Yoshihara, T | 2 |
| Hamabe, A | 1 |
| Okada, K | 1 |
| Oka, Y | 1 |
| Kawanaka, S | 1 |
| Taniguchi, S | 1 |
| Adachi, S | 1 |
| Yoshioka, S | 3 |
| Ueshima, S | 1 |
| Higaki, N | 1 |
| Hayashida, H | 1 |
| Nezu, R | 2 |
| Tsuruta, S | 1 |
| Kimura, N | 1 |
| Ishido, K | 2 |
| Kudo, D | 1 |
| Sakuraba, S | 1 |
| Sawano, T | 1 |
| Suto, A | 1 |
| Aoki, M | 1 |
| Fukunari, H | 2 |
| Kawai, Y | 1 |
| Watanabe, A | 2 |
| Umebayashi, Y | 1 |
| Saito, T | 1 |
| Alexey, A | 1 |
| Ajioka, Y | 1 |
| Azama, T | 1 |
| Kitada, M | 1 |
| Noma, T | 1 |
| Takahashi, T | 6 |
| Miyazaki, Y | 2 |
| Kurokawa, Y | 4 |
| Tanaka, K | 1 |
| Makino, T | 3 |
| Nakajima, K | 3 |
| Yamasaki, M | 1 |
| Takahashi, R | 2 |
| Nagino, M | 3 |
| Kawada, J | 1 |
| Nishino, M | 1 |
| Hata, M | 1 |
| Tanizaki, K | 2 |
| Hoshino, H | 1 |
| Okano, M | 1 |
| Nagai, K | 1 |
| Kim, Y | 1 |
| Okuyama, M | 1 |
| Tsujinaka, T | 3 |
| Imamoto, H | 3 |
| Xu, B | 1 |
| Liu, Y | 1 |
| Lu, P | 1 |
| Ba, Y | 1 |
| Wu, L | 1 |
| Bai, Y | 1 |
| Zhang, S | 1 |
| Feng, J | 1 |
| Cheng, Y | 1 |
| Li, J | 1 |
| Wen, L | 1 |
| Yuan, X | 1 |
| Ma, C | 1 |
| Hu, C | 1 |
| Fan, Q | 1 |
| Wakasaki, T | 1 |
| Yasumatsu, R | 1 |
| Uchi, R | 1 |
| Taura, M | 1 |
| Matsuo, M | 1 |
| Komune, N | 1 |
| Nakagawa, T | 1 |
| Mitani, S | 1 |
| Kadowaki, S | 2 |
| Hasegawa, H | 1 |
| Wakatsuki, T | 1 |
| Tajika, M | 3 |
| Muro, K | 4 |
| Kohira, Y | 1 |
| Ishibashi, Y | 1 |
| Egawa, H | 1 |
| Yube, Y | 1 |
| Kaji, S | 1 |
| Kanda, S | 1 |
| Oka, S | 1 |
| Kajiyama, Y | 1 |
| Ito, T | 3 |
| Honma, Y | 1 |
| Hirano, H | 1 |
| Shoji, H | 2 |
| Okita, N | 1 |
| Iwasa, S | 1 |
| Ariake, K | 1 |
| Motoi, F | 3 |
| Mizuma, M | 1 |
| Ohtsuka, H | 2 |
| Nakagawa, K | 6 |
| Hata, T | 3 |
| Mitachi, K | 1 |
| Seki-Soda, M | 1 |
| Koshi, H | 1 |
| Yokoo, S | 1 |
| Takatori, E | 1 |
| Shoji, T | 1 |
| Suga, Y | 1 |
| Niinuma, H | 1 |
| Miura, Y | 1 |
| Kaido, Y | 1 |
| Takada, A | 1 |
| Kagabu, M | 1 |
| Takeuchi, S | 1 |
| Sugiyama, T | 2 |
| Okada, H | 1 |
| Taira, K | 1 |
| Tokunaga, S | 1 |
| Daga, H | 1 |
| Miyamoto, N | 1 |
| Nishijima, M | 1 |
| Sumitani, M | 1 |
| Syoji, S | 1 |
| Takeda, K | 3 |
| Nishio, M | 1 |
| Murakami, H | 1 |
| Ohyanagi, F | 1 |
| Kozuka, T | 1 |
| Ishikura, S | 1 |
| Naito, T | 1 |
| Kaira, K | 1 |
| Horiike, A | 1 |
| Nishimura, T | 2 |
| Fukunaga, M | 1 |
| Fukuzaki, T | 1 |
| Ohnishi, T | 2 |
| Tanaka, N | 1 |
| Takemasa, I | 2 |
| Yamamoto, H | 7 |
| Sekimoto, M | 1 |
| Yamashita, H | 1 |
| Okuma, K | 1 |
| Shiraishi, K | 1 |
| Ohtomo, K | 1 |
| Suzuki, Y | 1 |
| Ogiya, R | 1 |
| Oshitanai, R | 1 |
| Terao, M | 1 |
| Terada, M | 1 |
| Morioka, T | 1 |
| Tsuda, B | 1 |
| Niikura, N | 1 |
| Okamura, T | 2 |
| Saito, Y | 1 |
| Tokuda, Y | 1 |
| Yunokawa, M | 1 |
| Kodaira, M | 1 |
| Yonemori, K | 1 |
| Shimizu, C | 1 |
| Ando, M | 1 |
| Wada, T | 1 |
| Kunisaki, C | 4 |
| Hasegawa, S | 2 |
| Takagawa, R | 2 |
| Momiyama, M | 1 |
| Kosaka, T | 2 |
| Makino, H | 2 |
| Ono, HA | 2 |
| Akiyama, H | 2 |
| Endo, I | 2 |
| Akutsu, Y | 1 |
| Kono, T | 1 |
| Uesato, M | 1 |
| Hoshino, I | 1 |
| Narushima, K | 1 |
| Hanaoka, T | 1 |
| Tochigi, T | 1 |
| Semba, Y | 1 |
| Qin, W | 1 |
| Matsubara, H | 1 |
| Hamaguchi, T | 1 |
| Yoshimura, K | 3 |
| Fuse, N | 3 |
| Goto, M | 2 |
| Tanigawa, N | 1 |
| Shirao, K | 2 |
| Fujitani, K | 4 |
| Tamura, S | 2 |
| Matsuyama, J | 2 |
| Iijima, S | 4 |
| Kobayashi, K | 2 |
| Furukawa, H | 6 |
| Yutani, S | 1 |
| Komatsu, N | 1 |
| Yoshitomi, M | 1 |
| Matsueda, S | 1 |
| Yonemoto, K | 1 |
| Mine, T | 2 |
| Noguchi, M | 1 |
| Ishihara, Y | 1 |
| Yamada, A | 1 |
| Itoh, K | 1 |
| Sasada, T | 1 |
| Otsuka, H | 1 |
| Fujii, T | 2 |
| Toh, U | 1 |
| Iwakuma, N | 1 |
| Mishima, M | 1 |
| Takenaka, M | 1 |
| Kakuma, T | 1 |
| Shirouzu, K | 1 |
| Ishida, K | 1 |
| Fujishima, F | 1 |
| Ottomo, S | 1 |
| Oikawa, M | 1 |
| Shimamura, H | 1 |
| Takemura, S | 1 |
| Ono, F | 1 |
| Akada, M | 1 |
| Katayose, Y | 2 |
| Egawa, S | 2 |
| Takiuchi, H | 5 |
| Morimoto, T | 2 |
| Maruyama, K | 1 |
| Otsuji, T | 1 |
| Omura, T | 1 |
| Nagata, T | 1 |
| Okumura, T | 1 |
| Yamagishi, F | 1 |
| Tajika, S | 1 |
| Nakajima, S | 1 |
| Kawabe, A | 1 |
| Tsukada, K | 1 |
| Naitoh, H | 1 |
| Murata, S | 1 |
| Kobayashi, H | 2 |
| Tani, T | 1 |
| Canbay, E | 1 |
| Mizumoto, A | 1 |
| Ichinose, M | 1 |
| Ishibashi, H | 1 |
| Sako, S | 1 |
| Hirano, M | 1 |
| Takao, N | 1 |
| Yonemura, Y | 2 |
| Koizumi, W | 3 |
| Kim, YH | 1 |
| Fujii, M | 7 |
| Kim, HK | 1 |
| Lee, KH | 5 |
| Hara, T | 1 |
| Cho, JY | 1 |
| Hosaka, H | 1 |
| Tsuji, A | 5 |
| Takagane, A | 2 |
| Inokuchi, M | 1 |
| Tanabe, K | 6 |
| Ogura, M | 1 |
| Morizane, C | 1 |
| Hiraoka, N | 1 |
| Kondo, S | 2 |
| Ueno, H | 2 |
| Ohno, I | 1 |
| Shimizu, S | 2 |
| Mitsunaga, S | 1 |
| Nakamura, A | 2 |
| Itasaka, S | 1 |
| Takaori, K | 1 |
| Kawaguchi, Y | 1 |
| Shibuya, K | 1 |
| Yoshimura, M | 1 |
| Mizowaki, T | 1 |
| Uemoto, S | 2 |
| Hiraoka, M | 1 |
| Hu, JB | 1 |
| Sun, XN | 1 |
| Gu, BX | 1 |
| Wang, Q | 2 |
| Hu, WX | 1 |
| Wang, M | 1 |
| Wu, M | 1 |
| Wang, W | 1 |
| Wang, Y | 2 |
| Higashino, M | 2 |
| Kawata, R | 1 |
| Lee, K | 1 |
| Nishikawa, S | 1 |
| Ichihara, S | 1 |
| Uesugi, Y | 1 |
| Cabalag, CS | 1 |
| Chan, ST | 1 |
| Kaneko, Y | 1 |
| Duong, CP | 1 |
| Takashima, T | 3 |
| Nakayama, T | 1 |
| Yoshidome, K | 1 |
| Kawajiri, H | 1 |
| Kamigaki, S | 1 |
| Tsurutani, J | 1 |
| Arai, T | 1 |
| Komoike, Y | 1 |
| Masuda, N | 2 |
| Miyauchi, K | 1 |
| Sakamoto, J | 12 |
| Taguchi, T | 4 |
| Higashi, D | 1 |
| Egawa, Y | 1 |
| Hirano, Y | 1 |
| Hirano, K | 2 |
| Miyake, T | 1 |
| Uwatoko, S | 1 |
| Abe, S | 2 |
| Mikami, K | 1 |
| Futami, K | 1 |
| Maekawa, T | 2 |
| Inoue, R | 1 |
| Miyazaki, M | 1 |
| Peng, PJ | 1 |
| Cheng, H | 1 |
| Ou, XQ | 1 |
| Zeng, LJ | 1 |
| Wu, X | 1 |
| Liu, YM | 1 |
| Lin, Z | 1 |
| Tang, YN | 1 |
| Wang, SY | 1 |
| Zhang, HY | 1 |
| Chen, ZB | 1 |
| Emoto, S | 1 |
| Kitayama, J | 1 |
| Ishigami, H | 1 |
| Lee, SJ | 1 |
| Park, SH | 1 |
| Park, JO | 1 |
| Lim, DH | 1 |
| Park, YS | 1 |
| Lim, HY | 1 |
| Sueda, T | 2 |
| Sakai, D | 2 |
| Nishimura, J | 2 |
| Ezoe, S | 1 |
| Abe, K | 1 |
| Okui, N | 1 |
| Hata, D | 1 |
| Shiba, H | 1 |
| Futagawa, Y | 1 |
| Aiba, K | 1 |
| Yanaga, K | 3 |
| Nogami, N | 2 |
| Takigawa, N | 1 |
| Hotta, K | 2 |
| Segawa, Y | 2 |
| Kozuki, T | 1 |
| Oze, I | 1 |
| Kishino, D | 1 |
| Aoe, K | 1 |
| Ueoka, H | 1 |
| Kuyama, S | 1 |
| Harita, S | 1 |
| Hosokawa, S | 1 |
| Gemba, K | 1 |
| Shibayama, T | 1 |
| Tabata, M | 1 |
| Takemoto, M | 1 |
| Kanazawa, S | 1 |
| Tanimoto, M | 1 |
| Kiura, K | 1 |
| Saito, M | 1 |
| Kiyozaki, H | 1 |
| Takata, O | 1 |
| Suzuki, K | 1 |
| Rikiyama, T | 2 |
| Sasaki, T | 3 |
| Isayama, H | 2 |
| Nakai, Y | 2 |
| Ito, Y | 4 |
| Yasuda, I | 1 |
| Toda, N | 1 |
| Yagioka, H | 2 |
| Matsubara, S | 2 |
| Hanada, K | 1 |
| Maguchi, H | 1 |
| Kamada, H | 1 |
| Hasebe, O | 1 |
| Mukai, T | 1 |
| Okabe, Y | 1 |
| Maetani, I | 1 |
| Koike, K | 1 |
| Kim, HS | 3 |
| Kim, HY | 1 |
| Zang, DY | 3 |
| Oh, HS | 1 |
| Jeon, JY | 1 |
| Cho, JW | 1 |
| Park, CK | 1 |
| Kim, MJ | 1 |
| Ha, HI | 1 |
| Han, B | 1 |
| Song, H | 1 |
| Kwon, JH | 1 |
| Choi, DR | 1 |
| Jung, JY | 1 |
| Zhong, DT | 1 |
| Wu, RP | 1 |
| Wang, XL | 1 |
| Huang, XB | 1 |
| Lin, MX | 1 |
| Lan, YQ | 1 |
| Chen, Q | 1 |
| Tsukahara, K | 1 |
| Kubota, A | 1 |
| Hasegawa, Y | 3 |
| Takemura, H | 1 |
| Terada, T | 1 |
| Nagahara, K | 1 |
| Nakatani, H | 1 |
| Yoshino, K | 1 |
| Higaki, Y | 1 |
| Iwae, S | 1 |
| Beppu, T | 1 |
| Hanamure, Y | 1 |
| Tomita, K | 2 |
| Kohno, N | 2 |
| Kawabata, K | 1 |
| Fukushima, M | 5 |
| Teramukai, S | 4 |
| Hishida, T | 1 |
| Tsuboi, M | 1 |
| Shukuya, T | 1 |
| Takamochi, K | 1 |
| Sakurai, H | 1 |
| Yoh, K | 1 |
| Kunitoh, H | 1 |
| Kaneko, J | 1 |
| Isogai, J | 1 |
| Hasegawa, K | 1 |
| Matsui, T | 3 |
| Aoyagi, H | 1 |
| Maejima, S | 1 |
| Kabashima, A | 2 |
| Kitagawa, D | 1 |
| Kondo, N | 2 |
| Teramoto, S | 2 |
| Saito, G | 1 |
| Funahashi, T | 1 |
| Adachi, E | 1 |
| Yamamoto, D | 1 |
| Iwase, S | 2 |
| Tsubota, Y | 1 |
| Ariyoshi, K | 1 |
| Kawaguchi, T | 1 |
| Miyaji, T | 1 |
| Sueoka, N | 1 |
| Yamamoto, C | 1 |
| Odagiri, H | 1 |
| Nagumo, Y | 1 |
| Uehara, K | 2 |
| Maeda, A | 2 |
| Sakamoto, E | 2 |
| Hiramatsu, K | 2 |
| Takeuchi, E | 2 |
| Tojima, Y | 2 |
| Yatsuya, H | 1 |
| Qiu, M | 1 |
| Peng, XC | 1 |
| Bi, F | 1 |
| Xu, F | 1 |
| Li, ZP | 1 |
| Shen, YL | 1 |
| Liu, JY | 1 |
| Zhao, YQ | 1 |
| Cao, D | 1 |
| Gou, HF | 1 |
| Yang, Y | 2 |
| Chen, Y | 2 |
| Yi, C | 1 |
| Kanda, M | 1 |
| Murotani, K | 1 |
| Kobayashi, D | 2 |
| Tanaka, C | 1 |
| Yamada, S | 2 |
| Nakayama, G | 1 |
| Sugimoto, H | 1 |
| Fujiwara, M | 1 |
| Park, YI | 1 |
| Hyodo, I | 2 |
| Nam, BH | 1 |
| Yoo, C | 1 |
| Ryoo, BY | 2 |
| Song, EK | 2 |
| Cho, SH | 4 |
| Yang, SH | 2 |
| Shin, DB | 2 |
| Park, SR | 2 |
| Shinozaki, K | 1 |
| Takano, T | 1 |
| Tanigawa, T | 3 |
| Matoda, M | 1 |
| Yamamoto, A | 1 |
| Nomura, H | 1 |
| Okamoto, S | 1 |
| Kondo, E | 1 |
| Omatsu, K | 1 |
| Takeshima, N | 1 |
| Nishina, T | 2 |
| Hamamoto, Y | 1 |
| Kawai, H | 1 |
| Nakayama, N | 2 |
| Amagai, K | 1 |
| Mizusawa, J | 1 |
| Ohtsu, A | 3 |
| Sakaguchi, Y | 2 |
| Kinjo, N | 1 |
| Yamaguchi, S | 1 |
| Egashira, A | 2 |
| Minami, K | 1 |
| Morita, M | 2 |
| Toh, Y | 1 |
| Nakanishi, K | 2 |
| Mochizuki, Y | 2 |
| Ishigure, K | 1 |
| Kojima, H | 2 |
| Ishiyama, A | 1 |
| Fujitake, S | 1 |
| Shikano, T | 1 |
| Okabe, H | 2 |
| Ueda, S | 2 |
| Zaima, M | 1 |
| Tokuka, A | 1 |
| Ota, S | 1 |
| Kinjo, Y | 1 |
| Sakai, Y | 3 |
| Hironaka, S | 4 |
| Moriwaki, T | 1 |
| Nakajima, TE | 1 |
| Sekikawa, T | 1 |
| Matsumoto, S | 5 |
| Baba, H | 5 |
| Okubo, S | 1 |
| Yamazaki, M | 1 |
| Shim, HJ | 1 |
| Kim, KR | 1 |
| Hwang, JE | 1 |
| Bae, WK | 1 |
| Ryu, SY | 1 |
| Park, YK | 1 |
| Nam, TK | 1 |
| Chung, IJ | 2 |
| Murata, A | 1 |
| Maeda, K | 2 |
| Ikejiri, K | 1 |
| Munemoto, Y | 1 |
| Kotake, M | 1 |
| Suenaga, T | 1 |
| Matsuda, H | 1 |
| Kakeji, Y | 4 |
| Hamada, C | 2 |
| Saji, S | 7 |
| Maehara, Y | 5 |
| Soh, J | 1 |
| Okumura, N | 1 |
| Nakata, M | 1 |
| Nakamura, H | 2 |
| Fukuda, M | 1 |
| Kataoka, M | 1 |
| Kajiwara, S | 1 |
| Sano, Y | 1 |
| Aoe, M | 1 |
| Kataoka, K | 1 |
| Matsuo, K | 3 |
| Toyooka, S | 1 |
| Date, H | 1 |
| Tomioku, M | 1 |
| Yazawa, N | 1 |
| Furukawa, D | 1 |
| Izumi, H | 1 |
| Mashiko, T | 1 |
| Ozawa, S | 1 |
| Sadahiro, S | 1 |
| Yasuda, S | 1 |
| Hirabayashi, K | 1 |
| Nakagohri, T | 1 |
| Mabuchi, S | 1 |
| Yokoi, E | 1 |
| Owa, T | 1 |
| Kozasa, K | 1 |
| Yamashita, M | 1 |
| Kobayashi, E | 1 |
| Tomimatsu, T | 1 |
| Yoki, T | 1 |
| Tsutui, T | 1 |
| Kimura, T | 2 |
| Taki, T | 1 |
| Hoya, Y | 1 |
| Nakayoshi, T | 1 |
| Okamoto, T | 1 |
| Sekine, H | 1 |
| Mitsumori, N | 3 |
| Egashira, S | 1 |
| Kajihara, I | 1 |
| Kanemaru, H | 1 |
| Uemura-Kiyohara, M | 1 |
| Yamada-Kanazawa, S | 1 |
| Nakahara, S | 1 |
| Nagamoto, E | 1 |
| Fukushima, S | 1 |
| Jinnin, M | 1 |
| Inoue, Y | 3 |
| Ihn, H | 1 |
| Yeo, W | 1 |
| Lam, KO | 1 |
| Law, AL | 1 |
| Lee, CC | 1 |
| Chiang, CL | 1 |
| Au, KH | 1 |
| Mo, FK | 1 |
| So, TH | 1 |
| Lam, KC | 1 |
| Ng, WT | 1 |
| Li, L | 1 |
| Hoshino, S | 1 |
| Sugano, T | 1 |
| Kitamura, T | 1 |
| Furukawa, M | 1 |
| Aragane, K | 1 |
| Lee, JL | 3 |
| Kang, HJ | 3 |
| Kim, JG | 2 |
| Chang, HM | 3 |
| Kim, TW | 3 |
| Baek, JH | 3 |
| Min, YJ | 1 |
| Matsumoto, M | 1 |
| Udagawa, I | 1 |
| Yasutomi, J | 1 |
| Kusashio, K | 1 |
| Kasagawa, T | 1 |
| Tonooka, T | 1 |
| Tashima, Y | 1 |
| Irabu, S | 1 |
| Nobumoto, D | 1 |
| Suzuki, M | 4 |
| Fukao, K | 1 |
| Osaki, Y | 2 |
| Tokudome, N | 1 |
| Sugihara, T | 1 |
| Takahashi, S | 3 |
| Iwase, T | 1 |
| Hatake, K | 1 |
| Lee, JJ | 1 |
| Kim, SY | 1 |
| Song, HS | 2 |
| Hong, YS | 3 |
| Choi, IS | 1 |
| Lee, YY | 1 |
| Woo, IS | 1 |
| Choi, JH | 1 |
| Nakashima, K | 1 |
| Taku, K | 3 |
| Kojima, T | 3 |
| Seol, YM | 1 |
| Song, MK | 1 |
| Choi, YJ | 1 |
| Kim, GH | 1 |
| Shin, HJ | 1 |
| Song, GA | 1 |
| Chung, JS | 1 |
| Cho, GJ | 1 |
| Uemura, T | 1 |
| Fujimitsu, Y | 1 |
| Kure, N | 1 |
| Tokunaga, N | 1 |
| Itaba, S | 1 |
| Yoshinaga, S | 1 |
| Murao, H | 1 |
| Akiho, H | 1 |
| Nagai, E | 1 |
| Goto, A | 2 |
| Takayanagi, R | 1 |
| Ono, A | 1 |
| Yoshino, T | 2 |
| Yamashita, T | 4 |
| Shinden, S | 1 |
| Watabe, T | 1 |
| Shiotani, A | 1 |
| Sadanaga, N | 1 |
| Takahashi, I | 4 |
| Yashima, Y | 1 |
| Kogure, H | 1 |
| Arizumi, T | 1 |
| Togawa, O | 1 |
| Sasahira, N | 1 |
| Tsujino, T | 1 |
| Tada, M | 1 |
| Kawabe, T | 1 |
| Omata, M | 1 |
| Suzuki, S | 6 |
| Ishikawa, K | 2 |
| Yamada, Y | 1 |
| Akasaka, O | 1 |
| Miwa, H | 1 |
| Ando, T | 1 |
| Koh, R | 1 |
| Kasama, M | 1 |
| Matsueda, R | 1 |
| Anan, H | 1 |
| Ishii, Y | 1 |
| Takayama, T | 3 |
| Asai, S | 1 |
| Nishijima, W | 1 |
| Tsukuda, M | 2 |
| Ishitoya, J | 1 |
| Yamane, H | 1 |
| Homma, A | 1 |
| Tomita, T | 1 |
| Sugiura, Y | 1 |
| Takeuchi, K | 2 |
| Kakizaki, T | 1 |
| Kaseda, S | 1 |
| Kadono, K | 1 |
| Park, T | 1 |
| Nakano, D | 2 |
| Matsumoto, H | 3 |
| Iwasaki, Y | 5 |
| Iwanaga, T | 2 |
| Fujiwara, N | 1 |
| Tamai, S | 1 |
| Matsumura, H | 1 |
| Naitou, A | 1 |
| Hashimoto, K | 1 |
| Yokoyama, S | 1 |
| Fukushima, Y | 1 |
| Nishishou, I | 1 |
| Nomura, T | 2 |
| Sasaki, Y | 2 |
| Taniguchi, M | 1 |
| Ookubo, K | 1 |
| Ootsuka, M | 1 |
| Akitake, H | 1 |
| Hama, N | 1 |
| Kashiwazaki, M | 1 |
| Tsujie, M | 2 |
| Ebisui, C | 2 |
| Fujimoto, T | 2 |
| Igarashi, Y | 1 |
| Yamanaka, C | 1 |
| Komori, T | 1 |
| Matsumoto, T | 1 |
| Takachi, K | 1 |
| Nishioka, K | 1 |
| Ami, K | 1 |
| Nagahama, T | 1 |
| Ohara, T | 1 |
| Ganno, H | 1 |
| Hataji, K | 1 |
| Kurokawa, T | 1 |
| Fukuda, A | 1 |
| Andou, M | 1 |
| Tei, S | 1 |
| Arai, K | 4 |
| Tomokuni, A | 1 |
| Marubashi, S | 4 |
| Nagano, H | 5 |
| Takeda, Y | 3 |
| Tanemura, M | 2 |
| Kitagawa, T | 2 |
| Monden, M | 5 |
| Machida, H | 1 |
| Tominaga, K | 1 |
| Yano, H | 2 |
| Nobuhara, Y | 1 |
| Matuoka, T | 1 |
| Yo, T | 1 |
| Yokoo, H | 1 |
| Kamiyama, T | 1 |
| Tahara, M | 2 |
| Fukumori, D | 1 |
| Kamachi, H | 1 |
| Matsushita, M | 1 |
| Todo, S | 2 |
| Jingu, K | 1 |
| Ariga, H | 2 |
| Kaneta, T | 2 |
| Takai, Y | 1 |
| Katja, L | 1 |
| Narazaki, K | 1 |
| Metoki, T | 1 |
| Fujimoto, K | 2 |
| Umezawa, R | 1 |
| Ogawa, Y | 1 |
| Nemoto, K | 2 |
| Koto, M | 1 |
| Mitsuya, M | 1 |
| Matsufuji, N | 1 |
| Kim, JY | 1 |
| Do, YR | 1 |
| Park, KU | 1 |
| Chae, YS | 1 |
| Kim, MK | 1 |
| Ryoo, HM | 1 |
| Bae, SH | 1 |
| Hozumi, Y | 1 |
| Murakami, S | 2 |
| Mitsuyama, S | 1 |
| Ohmura, T | 1 |
| Yajima, T | 1 |
| Tokumoto, N | 1 |
| Ohdan, H | 1 |
| Araki, K | 2 |
| Okano, S | 1 |
| Kiyota, N | 1 |
| Zenda, S | 1 |
| Kawashima, M | 1 |
| Hayashi, R | 1 |
| Minami, H | 2 |
| Oh, SY | 1 |
| Kwon, HC | 1 |
| Jeong, SH | 1 |
| Joo, YT | 1 |
| Lee, YJ | 1 |
| Kang, MH | 1 |
| Go, SI | 1 |
| Lee, GW | 1 |
| Kim, Hg | 1 |
| Kang, JH | 1 |
| Takahashi, M | 4 |
| Fujii, S | 1 |
| Kimura, J | 1 |
| Kameda, K | 1 |
| Kito, F | 1 |
| Kanai, M | 2 |
| Tsumura, T | 1 |
| Asada, M | 1 |
| Suzuki, C | 1 |
| Niimi, M | 1 |
| Nitta, T | 1 |
| Yasuchika, K | 1 |
| Taura, K | 1 |
| Mori, Y | 2 |
| Hamada, A | 1 |
| Inoue, N | 1 |
| Tada, S | 1 |
| Yanagihara, K | 1 |
| Yazumi, S | 1 |
| Chiba, T | 1 |
| Ikai, I | 1 |
| Hatano, E | 2 |
| Ueda, Y | 2 |
| Yamagishi, H | 2 |
| Ichikawa, D | 2 |
| Morii, J | 2 |
| Koizumi, K | 2 |
| Kakihara, N | 2 |
| Shimotsuma, M | 2 |
| Taniguchi, F | 1 |
| Aragane, H | 1 |
| Nishi, H | 1 |
| Itokawa, Y | 1 |
| Naito, S | 1 |
| Eto, M | 1 |
| Shinohara, N | 1 |
| Tomita, Y | 1 |
| Fujisawa, M | 1 |
| Namiki, M | 1 |
| Nishikido, M | 1 |
| Usami, M | 1 |
| Tsukamoto, T | 1 |
| Akaza, H | 1 |
| Katsuno, M | 1 |
| Watanabe, N | 2 |
| Sugio, Y | 1 |
| Tachibana, S | 1 |
| Tani, Y | 1 |
| Sato, N | 1 |
| Zusho, H | 1 |
| Sunaga, T | 1 |
| Harada, N | 2 |
| Kakita, T | 1 |
| Funayama, Y | 1 |
| Tokumura, H | 1 |
| Toshima, T | 1 |
| Fukuyama, S | 1 |
| Musya, H | 1 |
| Matsumura, N | 1 |
| Sasaki, H | 1 |
| Yasumoto, A | 1 |
| Kogashiwa, Y | 1 |
| Yamauchi, K | 1 |
| Nagafuji, H | 1 |
| Matsuda, T | 1 |
| Tsubosaka, T | 1 |
| Karaho, T | 1 |
| Maruyama, T | 1 |
| Seto, T | 1 |
| Ichinose, Y | 1 |
| Shinkai, T | 1 |
| Minato, K | 1 |
| Seki, N | 1 |
| Eguchi, K | 1 |
| Nishikawa, M | 1 |
| Takeda, M | 1 |
| Okamoto, I | 1 |
| Hirabayashi, N | 4 |
| Kitano, M | 2 |
| Morikita, T | 1 |
| Fujishima, H | 1 |
| Nakano, S | 1 |
| Maejima, K | 1 |
| Tokunaga, A | 2 |
| Kiyama, T | 1 |
| Kanno, H | 1 |
| Bou, H | 1 |
| Uchida, E | 1 |
| Shimabukuro, R | 1 |
| Shiraishi, T | 1 |
| Nishizaki, T | 2 |
| Endo, W | 1 |
| Fujie, Y | 1 |
| Shimizu, K | 1 |
| Yoshioka, A | 1 |
| Hojou, S | 1 |
| Maeura, Y | 1 |
| Nakamura, M | 3 |
| Morimoto, J | 1 |
| Amano, R | 1 |
| Noda, E | 1 |
| Inoue, T | 1 |
| Yamada, N | 1 |
| Yashiro, M | 1 |
| Onoda, N | 2 |
| Sawada, T | 1 |
| Taniguchi, H | 3 |
| Miyazaki, S | 1 |
| Kim, C | 1 |
| Danno, K | 1 |
| Kagara, N | 1 |
| Kanoh, T | 1 |
| Tohno, T | 1 |
| Nakano, Y | 1 |
| Kagawa, K | 1 |
| Monden, T | 1 |
| Imaoka, S | 1 |
| Kanamura, T | 1 |
| Kojima, Y | 1 |
| Fujita, S | 2 |
| Ikeda, N | 1 |
| Wada, H | 4 |
| Umeshita, H | 1 |
| Choi, YH | 2 |
| Lee, SS | 1 |
| Narahara, H | 2 |
| Iishi, H | 1 |
| Sakata, Y | 3 |
| Mitachi, Y | 2 |
| Kamano, T | 1 |
| Oikawa, K | 1 |
| Kambe, M | 1 |
| Shirasaka, T | 2 |
| Tanaka, Y | 2 |
| Oda, H | 1 |
| Tajima, Y | 1 |
| Sakurai, J | 1 |
| Wakasugi, T | 1 |
| Tatebe, S | 1 |
| Kitajima, M | 3 |
| Sakuma, T | 1 |
| Deguchi, R | 1 |
| Takashimizu, S | 1 |
| Ogasawara, F | 1 |
| Numata, M | 1 |
| Ohtani, Y | 1 |
| Sato, S | 1 |
| Iwata, Y | 1 |
| Yuki, S | 1 |
| Sogabe, S | 1 |
| Fukushima, H | 1 |
| Iwanaga, I | 1 |
| Kudo, M | 1 |
| Tateyama, M | 1 |
| Meguro, T | 1 |
| Uebayashi, M | 1 |
| Saga, A | 1 |
| Asaka, M | 1 |
| Satoh, S | 2 |
| Ozaki, N | 1 |
| Sakabayashi, S | 1 |
| Yamada, H | 1 |
| Horie, A | 1 |
| Iketani, S | 1 |
| Kanai, I | 1 |
| Nakatani, Y | 1 |
| Hamada, Y | 1 |
| Tanabe, S | 1 |
| Nishimura, K | 1 |
| Takagi, S | 1 |
| Ae, T | 1 |
| Nakatani, K | 1 |
| Naruke, A | 1 |
| Katada, C | 1 |
| Yakabe, T | 1 |
| Noshiro, H | 1 |
| Ikeda, O | 1 |
| Miyoshi, A | 1 |
| Kitajima, Y | 1 |
| Asahina, H | 1 |
| Sekine, I | 1 |
| Horinouchi, H | 1 |
| Takiguchi, N | 1 |
| Takagi, M | 1 |
| Tokunaga, Y | 1 |
| Fukushima, R | 1 |
| Munakata, Y | 1 |
| Sekishita, Y | 1 |
| Mikayama, Y | 1 |
| Kodama, Y | 1 |
| Ajiki, T | 1 |
| Ioka, T | 1 |
| Murakami, Y | 2 |
| Uemura, K | 1 |
| Hashimoto, Y | 2 |
| Nakashima, A | 1 |
| Sakabe, R | 1 |
| Nakagawa, N | 1 |
| Nomiya, T | 1 |
| Kuroda, Y | 1 |
| Ichikawa, M | 1 |
| Ota, I | 1 |
| Takai, K | 1 |
| Kenjo, M | 1 |
| Mizota, A | 1 |
| Kondo, C | 2 |
| Ura, T | 2 |
| Tagawa, T | 1 |
| Akamine, S | 1 |
| Hisano, H | 1 |
| Taniguchi, Y | 1 |
| Kitamura, Y | 1 |
| Masuda, K | 1 |
| Yamamoto, K | 1 |
| Yoshida, H | 2 |
| Onogawa, T | 1 |
| Sawaki, A | 2 |
| Niwa, Y | 1 |
| Hamai, Y | 2 |
| Emi, M | 1 |
| Kushitani, K | 1 |
| Okada, M | 1 |
| Kim, HR | 1 |
| Kim, GM | 1 |
| Koh, YW | 1 |
| Kim, SH | 1 |
| Choi, EC | 1 |
| Hong, YK | 1 |
| Sung, JH | 1 |
| Cho, BC | 2 |
| Matsunaga, M | 1 |
| Onishi, H | 1 |
| Ishida, M | 1 |
| Miwa, K | 1 |
| Sunakawa, Y | 1 |
| Noguchi, T | 1 |
| Narabayashi, M | 1 |
| Oh, SC | 1 |
| Kim, JS | 1 |
| Nam, SH | 1 |
| Kim, BS | 1 |
| Yim, CY | 1 |
| Jeung, HC | 2 |
| Wakisaka, N | 1 |
| Endo, K | 1 |
| Murono, S | 1 |
| Yoshizaki, T | 1 |
| Sakaguchi, K | 1 |
| Ebata, T | 1 |
| Cui, Y | 1 |
| Yu, Y | 1 |
| Feng, Y | 1 |
| Liu, T | 1 |
| Kaneoka, Y | 1 |
| Teramachi, H | 1 |
| Shigeyasu, K | 1 |
| Kagawa, S | 1 |
| Uno, F | 1 |
| Nishizaki, M | 1 |
| Kishimoto, H | 1 |
| Gochi, A | 1 |
| Takahata, T | 1 |
| Nonaka, Y | 1 |
| Ninomiya, M | 2 |
| Fujiwara, T | 1 |
| Yano, T | 1 |
| Ono, H | 2 |
| Sato, M | 1 |
| Nishino, H | 1 |
| Shinozaki, T | 1 |
| Ichimura, K | 1 |
| Nakai, S | 1 |
| Morimoto, Y | 1 |
| Kurihara, Y | 1 |
| Sakurai, M | 1 |
| Konishi, K | 1 |
| Kobayashi, O | 1 |
| Sairenji, M | 1 |
| Motohashi, H | 1 |
| Imada, T | 3 |
| Kikkawa, N | 2 |
| Naoi, Y | 2 |
| Kurokawa, E | 2 |
| Ohta, K | 2 |
| Toge, T | 7 |
| Nishiyama, M | 4 |
| Honma, S | 2 |
| Hatanaka, F | 1 |
| Matsuo, S | 1 |
| Aratake, Y | 1 |
| Uchimura, K | 1 |
| Yokota, M | 1 |
| Sumii, T | 1 |
| Iguchi, H | 1 |
| Funakoshi, A | 1 |
| Tamura, H | 1 |
| Kurihara, H | 1 |
| Kitago, M | 1 |
| Ogihara, T | 1 |
| Nimura, H | 2 |
| Tsukagoshi, S | 1 |
| Nakajima, M | 1 |
| Atomi, Y | 1 |
| Kusano, M | 1 |
| Yoshiyuki, T | 1 |
| Oeda, M | 1 |
| Takiyama, W | 2 |
| Nagamine, I | 1 |
| Ohara, M | 1 |
| Oshita, A | 1 |
| Satou, Y | 1 |
| Kirihara, Y | 1 |
| Mukaida, H | 1 |
| Hisamatu, K | 1 |
| Matsuura, N | 1 |
| Akagi, Y | 1 |
| Ito, K | 1 |
| Yamamura, Y | 2 |
| Tanemura, H | 1 |
| Oshita, H | 1 |
| Miyashita, K | 1 |
| Saeki, T | 1 |
| Takashima, S | 2 |
| Sano, M | 2 |
| Horikoshi, N | 2 |
| Miura, S | 1 |
| Morimoto, K | 2 |
| Makari, Y | 1 |
| Yano, M | 2 |
| Kawabata, Y | 1 |
| Kusumoto, C | 1 |
| Miyamoto, K | 1 |
| Takeuchi, T | 2 |
| Mai, M | 2 |
| Tanigawara, Y | 1 |
| Takeo, Y | 1 |
| Tanaka, S | 1 |
| Hanyu, F | 1 |
| Nomura, M | 1 |
| Katsura, H | 1 |
| Sakao, J | 1 |
| Yokotani, H | 1 |
| Souda, S | 1 |
| Souma, I | 1 |
| Hayashi, N | 1 |
| Fukuchi, N | 1 |
| Izawa, H | 1 |
| Sakita, I | 1 |
| Hasuike, Y | 1 |
| Miyata, H | 1 |
| Sakon, M | 1 |
| Yamamoto, T | 1 |
| Damdinsuren, B | 2 |
| Miyamoto, A | 2 |
| Umeshita, K | 2 |
| Nakamori, S | 1 |
| Johira, H | 1 |
| Yunoki, S | 1 |
| Kawata, N | 1 |
| Hachisuka, Y | 1 |
| Uomoto, M | 1 |
| Hatano, H | 1 |
| Sanada, E | 1 |
| Watanabe, R | 1 |
| Ohmori, K | 1 |
| Miyata, N | 1 |
| Okita, K | 1 |
| Ojima, Y | 1 |
| Yamamura, S | 1 |
| Matsusaka, T | 1 |
| Morishita, Y | 1 |
| Kasakura, Y | 1 |
| Yamagata, M | 1 |
| Kochi, M | 2 |
| Ukon, K | 2 |
| Shimoyama, S | 1 |
| Imamura, K | 1 |
| Mafune, K | 1 |
| Kaminishi, M | 1 |
| Takenaka, A | 1 |
| Kurioka, H | 1 |
| Kanda, T | 1 |
| Yajima, K | 1 |
| Banba, T | 1 |
| Tanabe, T | 1 |
| Kosugi, S | 1 |
| Hatakeyama, K | 1 |
| Tokunaga, E | 1 |
| Ushiro, S | 1 |
| Shintani, S | 1 |
| Hino, S | 1 |
| Nakashiro, K | 1 |
| Hamakawa, H | 1 |
| Takakura, N | 1 |
| Sunagozaka, H | 1 |
| Kagaya, T | 1 |
| Kaneko, S | 1 |
| Wada, Y | 1 |
| Kashimura, H | 1 |
| Takayama, S | 1 |
| Kashiwagi, H | 1 |
| Ohshima, T | 2 |
| Yamada, R | 2 |
| Hatori, S | 2 |
| Yamazaki, Y | 1 |
| Suda, T | 1 |
| Takanashi, Y | 1 |
| Otsuka, Y | 1 |
| Rha, SY | 1 |
| Yoo, NC | 1 |
| Roh, JK | 1 |
| Roh, WJ | 1 |
| Ahn, JB | 1 |
| Mochiki, E | 1 |
| Ohno, T | 1 |
| Kamiyama, Y | 1 |
| Aihara, R | 1 |
| Haga, N | 1 |
| Ojima, H | 1 |
| Nakamura, J | 1 |
| Ohsawa, H | 1 |
| Nakabayashi, T | 1 |
| Asao, T | 1 |
| Kuwano, H | 1 |
| Uchida, K | 1 |
| Kuramochi, H | 1 |
| Nakajima, G | 1 |
| Ishiwata, R | 2 |
| Nagai, Y | 2 |
| Sohn, HJ | 1 |
| Lee, JS | 1 |
| Yamamoto, Y | 1 |
| Kida, A | 1 |
| Kono, N | 1 |
| Sugita, M | 2 |
| Kanamori, N | 1 |
| Wakabayashi, K | 1 |
| Sou, K | 1 |
| Tokita, H | 1 |
| Kato, F | 1 |
| Yamamoto, J | 1 |
| Okuda, N | 1 |
| Yagi, Y | 1 |
| Ichikawa, K | 1 |
| Yamaoka, T | 1 |
| Katou, T | 1 |
| Sakuramoto, S | 1 |
| Nashimoto, A | 1 |
| Kurita, A | 1 |
| Mizuno, N | 1 |
| Hoki, N | 1 |
| Ishikawa, H | 1 |
| Yamao, K | 1 |
| Arita, A | 1 |
| Fujimoto, M | 1 |
| Mochizuki, K | 1 |
| Watanabe, F | 1 |
| Iwagami, S | 1 |
| Yasutome, M | 1 |
| Egawa, T | 1 |
| Nagashima, A | 1 |
| Doi, M | 1 |
| Hayashi, S | 1 |
| Sekine, K | 1 |
| Shimizu, M | 1 |
| Yoshii, H | 1 |
| Ishida, H | 1 |
| Alsamarai, S | 1 |
| Zergebel, C | 1 |
| Furuie, T | 1 |
| Urrea, PD | 1 |
| Saif, MW | 1 |
| Inada, S | 1 |
| Tomidokoro, T | 1 |
| Hatano, T | 1 |
| Nishimura, A | 1 |
| Kawauchi, Y | 1 |
| Nikkuni, K | 1 |
| Yanagi, M | 1 |
| Nakadaira, K | 1 |
| Kurosaki, I | 1 |
| Ueki, H | 1 |
| Aoyama, H | 1 |
| Ota, J | 1 |
| Noguchi, S | 1 |
| Nishimoto, N | 1 |
| Kagawa, Y | 1 |
| Kim, R | 1 |
| Hirai, T | 1 |
| Inaba, Y | 1 |
| Watabe, S | 1 |
| Ohe, S | 1 |
| Kamio, Y | 1 |
| Chiba, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II, Single-center, Single-arm, Open-label Study of Nanoparticle Albumin-bound-paclitaxel (Nab-PTX) Plus S-1 and Sintilimab as Adjuvant Therapy in Patients With Stage IIIC Gastric Cancer[NCT04781413] | Phase 1/Phase 2 | 38 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| Infusional Fluorouracil and Weekly Docetaxel as First-line Therapy for Gastric Cancer With Bone Marrow Metastasis and Disseminated Intravascular Coagulation: a Multi-center, Phase II Trail[NCT04547153] | Phase 2 | 24 participants (Actual) | Interventional | 2021-01-15 | Completed | ||
| Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)[NCT00152217] | Phase 3 | 1,000 participants (Anticipated) | Interventional | 2001-09-30 | Completed | ||
| A Single-arm, Open Phase II Trial of CAPOX Combined With Bevacizumab Combined With Tirelizumab in First-line Treatment of PDL1 CPS < 5 Advanced Gastroesophageal Adenocarcinoma[NCT05299476] | Phase 2 | 30 participants (Anticipated) | Interventional | 2022-04-16 | Recruiting | ||
| ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer[NCT02746796] | Phase 2/Phase 3 | 680 participants (Anticipated) | Interventional | 2016-03-31 | Completed | ||
| Irinotecan Plus S1 Versus S1 in Patients With Previously Treated Advanced Esophageal Squamous Cell Carcinoma (ESWN 01 Trial): a Phase 3, Prospective,Multicenter, Randomised Study[NCT02319187] | Phase 3 | 240 participants (Anticipated) | Interventional | 2014-12-31 | Recruiting | ||
| Concurrent Radiotherapy and Weekly Chemotherapy of 5-fluorouracil and Cisplatin for Postoperative Locoregional Recurrence of Oesophageal Squamous Cell Carcinoma[NCT02325986] | Phase 2 | 46 participants (Anticipated) | Interventional | 2015-03-31 | Recruiting | ||
| A Phase III Study of Docetaxel and S-1 Versus S-1 in the Treatment of Advanced Gastric Cancer[NCT00287768] | Phase 3 | 628 participants (Anticipated) | Interventional | 2006-03-31 | Completed | ||
| Controlled Randomized Trial to Evaluate Efficacy of Adjuvant Chemotherapy Between S-1 and UFT for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Phase III Study[NCT00336947] | Phase 3 | 500 participants (Anticipated) | Interventional | 2006-04-30 | Active, not recruiting | ||
| Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction[NCT03519074] | Phase 2 | 48 participants (Anticipated) | Interventional | 2016-07-22 | Recruiting | ||
| Phase III Trial of 3-weekly vs. 5-weekly Schedule of S-1 Plus Cisplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer.[NCT00915382] | Phase 3 | 625 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359] | Phase 3 | 111 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552] | Phase 3 | 870 participants (Anticipated) | Interventional | 2013-08-19 | Recruiting | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449] | Phase 3 | 338 participants (Actual) | Interventional | 2012-12-31 | Completed | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| PhaseⅡSingle-center, Open-label, Exploratory Clinical Study of Apatinib in Combination With S1 for the Patients With Advanced Non-squamous Head and Neck Cancer[NCT02943252] | Phase 2 | 30 participants (Anticipated) | Interventional | 2016-10-31 | Recruiting | ||
| The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study[NCT05351398] | 54 participants (Anticipated) | Observational | 2022-04-30 | Not yet recruiting | |||
| Phase II Trial of Gemcitabine and S-1 for Patients With Advanced Biliary Tract Cancer[NCT02146703] | Phase 2 | 38 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| Phase II Clinical Study of Preoperative S-1/CDDP Combination Chemotherapy in Patients With Advanced Gastric Cancer[NCT00088816] | Phase 2 | 50 participants (Anticipated) | Interventional | 2003-04-30 | Active, not recruiting | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase I Study of S-1 in Combination With Radiotherapy in Locally Advanced or Recurrent Gastric Cancer[NCT01291407] | Phase 1 | 27 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Phase II Study of Docetaxel, Oxaliplatin and S-1 (DOS) in Patients With Advanced Gastric Cancer[NCT00525005] | Phase 2 | 44 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618] | Phase 2 | 41 participants (Actual) | Interventional | 2014-07-05 | Completed | ||
| [NCT01946061] | Phase 2 | 3 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to This study was stopped because of difficulties of supplying the drug.) | ||
| Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients[NCT00687843] | Phase 3 | 480 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Prospective Multicenter Randomized Controlled Clinical Trial for Comparison Between Laparoscopic and Open Subtotal Gastrectomy With D2 Lymph Node Dissection for Locally Advanced Gastric Cancer[NCT01456598] | 1,050 participants (Actual) | Interventional | 2011-11-21 | Completed | |||
| Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer[NCT02572050] | Phase 2 | 87 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| A Randomized Phase III Trial of Postoperative Chemotherapy or Chemo-radiotherapy for Locally Advanced Gastric Cancer After D2 Resection[NCT03601988] | Phase 3 | 408 participants (Anticipated) | Interventional | 2018-07-28 | Recruiting | ||
| Apatinib Plus S-1 for Advanced Gastric Cancer Refractory to Oxaliplatin Plus Capecitabine Combination Therapy: A Single-arm, Phase-2, Home-based Trial[NCT04338438] | Phase 2 | 37 participants (Actual) | Interventional | 2015-05-01 | Completed | ||
| A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery Using a Phase 3 [NCT03403296] | 640 participants (Actual) | Observational | 2016-07-13 | Completed | |||
| Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261] | Phase 3 | 556 participants (Anticipated) | Interventional | 2018-10-01 | Not yet recruiting | ||
| Multicenter Study on Comparison of Long-term Outcome Between Laparoscopic and Open Distal Subtotal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric Cancer[NCT01609309] | Phase 3 | 1,056 participants (Anticipated) | Interventional | 2012-09-30 | Active, not recruiting | ||
| Evaluation of Inflammatory Markers in Laparoscopic and Abdominal Hysterectomies: A Retrospective Study in Kocaeli, Northwest Turkey[NCT04184765] | 212 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for oxonic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Pharyngeal metastasis following living-donor liver transplantation for hepatocellular carcinoma: a case report and literature review.
Topics: Allografts; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Drug Combi | 2020 |
A systematic review and meta-analysis of gastric cancer treatment in patients with positive peritoneal cytology.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Int | 2015 |
Hypomanic episode during recurrent gastric cancer treatment: report of a rare case and literature review.
Topics: Aged; Antineoplastic Agents; Bipolar Disorder; Cisplatin; Drug Combinations; Female; Humans; Neoplas | 2012 |
[Weekly administration of paclitaxel with a short course of premedication for advanced or recurrent gastric cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2003 |
[Present status of chemotherapy for colorectal cancer in countries outside of Japan].
Topics: Administration, Oral; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb | 2003 |
[Combination therapy of a novel oral fluorouracil derivative TS-1 with low-dose cisplatin for recurrent and very advanced gastric cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Ph | 2004 |
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Do | 2004 |
[Combination chemotherapy of TS-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Combin | 2004 |
[Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Cli | 2006 |
[A patient with esophageal cancer recurrence responding to S-1 combined with cisplatin (CDDP)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
106 trials available for oxonic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Albumins; Antibodies, Monoclonal, Humanized; Antineoplas | 2022 |
S-1 or gemcitabine adjuvant therapy in resected pancreatic cancer: a cost-effectiveness analysis based on the JASPAC-01 trial.
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Cost-Benefit Analysis; Deoxycytidine; Di | 2020 |
Randomized phase II trial of S-1 plus cisplatin or docetaxel plus cisplatin with concurrent thoracic radiotherapy for inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2021 |
Randomized phase II study of SOX+B-mab versus SOX+C-mab in patients with previously untreated recurrent advanced colorectal cancer with wild-type KRAS (MCSGO-1107 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Colorectal Neop | 2021 |
A phase II trial of neoadjuvant chemoradiotherapy with intensity-modulated radiotherapy combined with gemcitabine and S-1 for borderline-resectable pancreatic cancer with arterial involvement.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arteri | 2017 |
Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female | 2018 |
Patient-Reported Outcome Results from the Open-Label Randomized Phase III SELECT BC Trial Evaluating First-Line S-1 Therapy for Metastatic Breast Cancer.
Topics: Aged; Antineoplastic Agents; Breast Neoplasms; Bridged-Ring Compounds; Drug Combinations; Female; Fl | 2018 |
S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Dr | 2018 |
Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Mo | 2018 |
Phase III study of cisplatin with or without S-1 in patients with stage IVB, recurrent, or persistent cervical cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 2018 |
Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Follow-Up Studies; H | 2018 |
A multicenter, open-label, phase II trial of S-1 plus carboplatin in advanced non-small cell lung cancer patients with interstitial lung disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; C | 2018 |
Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, | 2019 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2019 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2019 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2019 |
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (A
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug C | 2019 |
Concurrent chemoradiotherapy using cisplatin and S-1, followed by surgery for stage II/IIIA non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2019 |
Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Diseas | 2019 |
Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemothera | 2013 |
A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2013 |
A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2013 |
Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; | 2014 |
A phase II study of a personalized peptide vaccination for chemotherapy-resistant advanced pancreatic cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cis | 2013 |
Phase II clinical trial of metronomic chemotherapy with combined irinotecan and tegafur-gimeracil-oteracil potassium in metastatic and recurrent breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 2015 |
Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: results from a prospective multi-institutional phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Combined Modalit | 2013 |
Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404).
Topics: Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; | 2014 |
Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Collagen; Docetaxel; | 2014 |
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D | 2014 |
Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer.
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy | 2014 |
Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2015 |
A phase II study of cisplatin plus S-1 with concurrent thoracic radiotherapy for locally advanced non-small-cell lung cancer: the Okayama Lung Cancer Study Group Trial 0501.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemora | 2015 |
Treatment outcomes of chemotherapy between unresectable and recurrent biliary tract cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; De | 2014 |
Phase II study of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms | 2015 |
Randomized phase III trial of adjuvant chemotherapy with S-1 after curative treatment in patients with squamous-cell carcinoma of the head and neck (ACTS-HNC).
Topics: Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Drug Combinations; Female; Head and N | 2015 |
Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Capecitabine; Deoxycytidine; | 2015 |
Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Disease- | 2015 |
Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemor | 2015 |
Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched | 2015 |
Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Female; Humans; | 2016 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combin | 2016 |
Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
A phase II study of neoadjuvant chemotherapy with S-1 and cisplatin for stage III gastric cancer: KUGC03.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2016 |
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Topics: Adenocarcinoma; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Fre | 2016 |
A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem | 2016 |
A randomized phase III trial comparing S-1 versus UFT as adjuvant chemotherapy for stage II/III rectal cancer (JFMC35-C1: ACTS-RC).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2016 |
Randomized feasibility study of S-1 for adjuvant chemotherapy in completely resected Stage IA non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 0701.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Phase I Clinical Study of Irinotecan Plus S-1 in Patients With Advanced or Recurrent Cervical Cancer Previously Treated With Platinum-Based Chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ca | 2016 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi | 2008 |
A multi-center phase II study of S-1 plus paclitaxel as first-line therapy for patients with advanced or recurrent unresectable gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Comb | 2009 |
Outpatient chemotherapy with S-1 for recurrent head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2009 |
Phase II study of biweekly docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2009 |
Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Follow-Up St | 2010 |
Phase I/II study of s-1 plus cisplatin combination chemotherapy in patients with advanced/recurrent head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
Multicenter phase II trial of S-1, paclitaxel and cisplatin triplet combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Co | 2011 |
Randomized study of taxane versus TS-1 in women with metastatic or recurrent breast cancer (SELECT BC).
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Breast Ne | 2010 |
Phase I trial of combination chemotherapy with docetaxel, cisplatin and S-1 (TPS) in patients with locally advanced or recurrent/metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Dose-Response Rel | 2011 |
A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C | 2012 |
Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Surviva | 2011 |
A multi-institution phase II study of gemcitabine/S-1 combination chemotherapy for patients with advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidine; | 2011 |
Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Confidence Interval | 2010 |
Multicenter phase II trial of S-1 in patients with cytokine-refractory metastatic renal cell carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Dihydrouracil Dehydrogenase (NADP); Di | 2010 |
Phase I study of S-1 plus nedaplatin in patients with advanced/recurrent head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell; Cisplatin | 2010 |
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2011 |
Phase II study of sequential treatment with S-1 and cisplatin for metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic | 2011 |
Safety and efficacy of S-1 monotherapy in elderly patients with advanced gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Age Factors; Aged; Aged, 80 and over; Anemia; Anorexia; Antime | 2010 |
A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dos | 2011 |
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2011 |
Phase II trial of S-1 plus low-dose cisplatin for unresectable and recurrent gastric cancer (JFMC27-9902 Step2).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug | 2010 |
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; An | 2011 |
Phase II study of combined treatment with irinotecan and S-1 (IRIS) in patients with inoperable or recurrent advanced colorectal cancer (HGCSG0302).
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C | 2011 |
Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 2012 |
A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601).
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Admi | 2012 |
Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Dise | 2012 |
Phase I trial of oral S-1 combined with gemcitabine and cisplatin for advanced biliary tract cancer (KHBO1002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cisplatin; Deoxycytid | 2012 |
A phase I trial of S-1 with concurrent radiotherapy in patients with locally recurrent rectal cancer.
Topics: Aged; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Maximum Tolerated Dose; Mi | 2013 |
A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine S-1 for non-small-cell lung cancer: high completion and survival rates.
Topics: Administration, Oral; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-C | 2012 |
A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; C | 2012 |
Phase II trial of adjuvant chemotherapy with S-1 for colorectal liver metastasis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, | 2013 |
Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydroge | 2013 |
Multicenter phase II study of S-1 and docetaxel combination chemotherapy for advanced or recurrent gastric cancer patients with peritoneal dissemination.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; H | 2013 |
A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cispla | 2003 |
Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cisplatin; Dose-Response Relationsh | 2003 |
[Pilot study of TS-1 combined with lentinan in patients with unresectable or recurrent advanced gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul | 2003 |
[Efficacy and safety of novel oral fluoropyrimidine anticancer drug, TS-1 for advanced and recurrent gastric cancer patients].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Bilirubin; Drug Admini | 2003 |
[A phase I study of combination chemotherapy using TS-1 and pirarubicin (THP) for advanced gastric cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administratio | 2004 |
Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; | 2004 |
[A late phase II clinical study of S-1 in patients with progressed, refractory breast cancer].
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Breast Neoplasms; Diarrhea; Drug Administrat | 2004 |
A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug | 2004 |
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Do | 2004 |
Long-term outcome of S-1 and cisplatin combination therapy in patients with advanced or recurrent gastric cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pr | 2005 |
Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-R | 2005 |
Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2005 |
Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer.
Topics: Adult; Aged; Alopecia; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under | 2006 |
[Clinical trial of chemotherapy identified according to chemosensitivity assay for oral cancer patients with unresectable recurrent lesions].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administration Schedu | 2006 |
Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D | 2006 |
[Combination chemotherapy of S-1 and docetaxel on advanced and recurrent gastric cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administratio | 2006 |
[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug | 2006 |
A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dru | 2006 |
Phase I/II study of S-1 combined with paclitaxel in patients with unresectable and/or recurrent advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Combinations; | 2006 |
Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diarrhea; | 2008 |
A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC).
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2007 |
A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Combi | 2007 |
Multi-center phase II study for combination therapy with paclitaxel/doxifluridine to treat advanced/recurrent gastric cancer showing resistance to S-1 (OGSG 0302).
Topics: Adenocarcinoma; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Disease-Free | 2008 |
Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Dr | 2009 |
[An early phase II clinical study of S-1 in patients with breast cancer. S-1 Cooperative Study Group (Breast Cancer Working Group)].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Administrati | 1998 |
[A new therapeutic approach to advanced and recurrent gastric cancer by TS-1].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Dr | 2001 |
[The clinical effect of TS-1 in advanced and recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Combinations; Femal | 2002 |
196 other studies available for oxonic acid and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Survival Outcomes of Gemcitabine Plus S-1 Adjuvant Chemotherapy after Surgical Resection for Advanced Biliary Tract Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2021 |
S-1 facilitates canerpaturev (C-REV)-induced antitumor efficacy in a triple-negative breast cancer model.
Topics: Animals; Antimetabolites, Antineoplastic; CD8-Positive T-Lymphocytes; Drug Combinations; Fluorouraci | 2021 |
Effect and safety of anlotinib combined with S-1 for recurrent or metastatic esophageal cancer patients who refused or were intolerant to intravenous chemotherapy.
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Esophageal Neoplasms; Humans; Indoles; Neoplasm | 2021 |
CD33+ Immature Myeloid Cells Critically Predict Recurrence in Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2020 |
Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2020 |
[A Case of Large-Cell Neuroendocrine Carcinoma of the Stomach with Multiple Liver Metastases That Show Complete Response to Multidisciplinary Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Cisplatin; Gastrectomy; H | 2019 |
The efficacy and feasibility of adopting intravenous chemotherapy and oral S-1 as a sequential therapy for postoperative gastric cancer patients.
Topics: Administration, Oral; Adult; Aged; Chemotherapy, Adjuvant; Drug Combinations; Feasibility Studies; F | 2019 |
[Successful Administration of Alternate-Day, Low-Dose S-1 in a Patient with Recurrent Esophageal Cancer with a Poor Compliance Profile].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dr | 2019 |
Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer - A multi-institutional clinical study in Asia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo | 2020 |
[Preoperative C-reactive protein predicts recurrence after curative resection in advanced gastric cancer patients receiving postoperative adjuvant chemotherapy using S-1].
Topics: Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Chemotherapy, Adjuvant; Drug Com | 2020 |
Comparison of S-1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemot | 2020 |
Plasma microRNA profiles: identification of miR-1229-3p as a novel chemoresistant and prognostic biomarker in gastric cancer.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Cell Survival; Disease-Free Survival; D | 2020 |
Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1.
Topics: Chemotherapy, Adjuvant; Drug Combinations; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, L | 2020 |
[A Case of Successful Surgical Treatment for Paraaortic Lymph Nodes Recurrence of Gallbladder Cancer].
Topics: Aged; Drug Combinations; Gallbladder Neoplasms; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic | 2019 |
[A Case Report of Advanced Gastric Cancer with Synchronous Liver Metastasis Treated with Conversion Surgery after S-1 plus Oxaliplatin Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Liver | 2019 |
[A Case with Three Resections of the Pulmonary Metastases of a Distal Bile Duct Carcinoma].
Topics: Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts; Drug Combinations; Humans; L | 2019 |
[A Case of Curative Resection of Locally Advanced Gastric Cancer after Nutrition Therapy and Chemotherapy with S-1 and Oxaliplatin Using Elemental Diet Tube].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Food, Formulated; Gastrecto | 2019 |
[A Case of Curatively Resected Locally Recurrent Rectal Mucinous Adenocarcinoma Followed by Preoperative Chemoradiotherapy].
Topics: Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Chemoradiotherapy; Drug Combinations; Hum | 2019 |
[A Case of Conversion Surgery for an Initially Locally Advanced Unresectable Pancreatic Cancer after S-1 Chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Neoadjuvant Therapy; Neoplas | 2019 |
[A Case of Advanced Gastric Cancer with Liver Metastases Treated with Curative Conversion Therapy after S-1 plus Oxaliplatin].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Liver Neopla | 2019 |
[A Case of Recurrent Gastric Cancer with Clinical Complete Response after Ramucirumab plus Paclitaxel Therapy].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Gastre | 2019 |
[A Case of Gastric Endocrine Carcinoma with a Huge Liver Metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Gastrectomy; Humans; Liver Neoplasm | 2019 |
[A Case of Advanced Gastric Cancer with Right Gastroepiploic Vein Tumor Thrombus Treated by Preoperative S-1 plus CDDP That Resulted in Pathological Complete Response].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hum | 2019 |
Efficacy of adjuvant chemotherapy with S-1 in stage II oral squamous cell carcinoma patients: A comparative study using the propensity score matching method.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2020 |
[A Case of Long-Term Survival with Far Advanced Gastric Cancer after Multidisciplinary Treatments, including Conversion Surgery].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Lymphatic Metastasis; Mal | 2020 |
[Long-Term Survival for a Patient with StageⅣ Gastric Cancer with Multiple Liver Metastases for Ten Years Who Was Treated with Only S-1Chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; Humans; | 2020 |
Comparison of 2- and 4-week S-1 administration as adjuvant chemotherapy for advanced gastric cancer.
Topics: Aged; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectomy; Humans; Male; Middle Aged; Neo | 2020 |
Low-dose apatinib and tegafur-gimeracil-oteracil as palliative treatment in recurrent cervical cancer patients with poor performance status: A case series.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans; Middle Aged | 2020 |
Prediction of Efficacy of Postoperative Chemotherapy by DNA Methylation of CDO1 in Gastric Cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Ch | 2020 |
[A Long Term Survival Case of Gastric Cancer with Peritoneal Dissemination Responding to Intraperitoneal Chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Human | 2020 |
Adjuvant Chemotherapy vs. Surgery Alone for pT3N0M0 Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Gastrectomy; Humans; Neoplas | 2021 |
[A Case of Type 4 Gastric Cancer with Peritoneal Dissemination Successfully Treated with Conversion Surgery after Intensive S-1 plus Oxaliplatin Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gastrectomy; Humans | 2021 |
[A Case of Advanced Gastric Cancer with Extensive Lymph Node Metastasis That Showed pCR to Preoperative Chemotherapy Containing SP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrect | 2020 |
[A Long-Survived Case of Gastric Cancer with Multiple Liver Metastases Who Underwent Gastrectomy and Received Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Gastrectomy; Hum | 2020 |
[Pathological Complete Response in a Case of Advanced Gastric Cancer with Para-Aortic Lymph Nodes Metastasis Treated by Preoperative Chemotherapy with S-1 and Oxaliplatin(SOX Therapy)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Lymph | 2020 |
Clinical Impact of the Prognostic Nutritional Index as a Predictor of Outcomes in Patients with Stage II/III Gastric Cancer: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Docetaxel; Drug Combinations; Female; Gastrectomy; | 2021 |
Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Ne | 2021 |
[A Long‒Term Survival Case of Gastric Cancer with Disseminated Intravascular Coagulation due to Myelocarcinomatosis Treated with S‒1 plus Oxaliplatin Therapy].
Topics: Adult; Disseminated Intravascular Coagulation; Drug Combinations; Humans; Male; Neoplasm Recurrence, | 2021 |
Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Ch | 2021 |
Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Drug Combinations; Female; Humans; M | 2021 |
[Choroidal metastasis from gastric cancer 8 years after surgery].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choroid; Drug Combinations; | 2021 |
Complete circumferential lymphadenectomy around the superior mesenteric artery with preservation of nerve plexus reduces locoregional recurrence after pancreatoduodenectomy for resectable pancreatic ductal adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreati | 2021 |
Tolerability and safety of adjuvant chemoradiotherapy with S-1 after limited surgery for T1 or T2 lower rectal cancer.
Topics: Chemoradiotherapy, Adjuvant; Humans; Neoplasm Recurrence, Local; Oxonic Acid; Prospective Studies; P | 2021 |
High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2021 |
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva | 2017 |
Chemotherapy for alpha-fetoprotein producing gastric cancers expressing human epidermal growth factor receptor 2.
Topics: Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Ant | 2018 |
Characterization of Prognostic Factors and the Efficacy of Adjuvant S-1 Chemotherapy in Patients with Post-surgery Extrahepatic Bile Duct Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; | 2017 |
Successful gamma knife radiosurgery combined with S-1 in an elderly man with local recurrent pancreatic cancer: A case report.
Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Drug Combinations; Follow-Up Studies; Humans; Male; Ne | 2017 |
Risk factors for severe neutropenia induced by combination therapy of S-1 and cisplatin in patients with advanced/recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; H | 2018 |
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap | 2018 |
Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combin | 2018 |
Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Carcinoma, Papillary; Carcino | 2018 |
The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen; Carcinoma, | 2018 |
Clinical Relevance of Postoperative Neutrophil-Lymphocyte Ratio (NLR) to Recurrence After Adjuvant Chemotherapy of S-1 for Gastric Cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality | 2018 |
Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Feasibility Stud | 2018 |
Successful treatment of microcystic adnexal carcinoma on the philtrum with oral S-1 monotherapy.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Skin Appendage; Chemotherapy | 2019 |
[A Case of Advanced Gastric Cancer with Peritoneal Dissemination after Gastrectomy Effectively Treated with Combination Chemotherapy of Ramucirumab and Paclitaxel].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherap | 2018 |
[A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis Treated with Conversion Surgery after S-1 plus Oxaliplatin Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Gastrectomy; Humans; Lymph Node Excision; Lymp | 2018 |
[A Case of Locally Advanced Gastric Cancer Treated with Chemoradiotherapy before Surgical Resection].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Female; Gastrectomy; Humans | 2018 |
[Three Cases of Advanced Gastric Cancer with Peritoneal Dissemination Successfully Treated with S-1 and Docetaxel Combination Chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Female; Gastrect | 2018 |
[A Case of Pancreatic Acinar Cell Carcinoma in a Young Woman without Recurrence after Systemic Chemotherapy Using S-1].
Topics: Adult; Carcinoma, Acinar Cell; Drug Combinations; Female; Humans; Neoplasm Recurrence, Local; Oxonic | 2018 |
[Two Cases of Surgical Treatment for Disseminated Gastric Carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug C | 2018 |
[Adjuvant Chemotherapy and the Prognosis of ypStageⅠ Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations | 2019 |
[Multi-Look Staging Laparoscopy and Conversion Surgery for Gastric Cancer with Peritoneal Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Gastrectomy; Humans; Laparoscopy; | 2019 |
Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Drug Combinations; Female; Gastrectom | 2019 |
[A Case of Recurrent Gastric Cancer Successfully Treated by S-1 Chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Humans | 2019 |
Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; C | 2020 |
Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuva | 2019 |
[A Case of Advanced Gastric Cancer with Pathological Complete Response after Chemotherapy(S-1/Cisplatin)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Gastrect | 2019 |
S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combination | 2019 |
Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuv | 2019 |
Histopathological changes in tumor budding between biopsy and resected specimens from patients treated with preoperative S-1 chemotherapy for oral cancer.
Topics: Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Squamous Cell; Drug Combinations; Humans; Mouth | 2019 |
A pilot study of oxaliplatin with oral S-1 as second-line chemotherapy for patients with recurrent adenocarcimona of the uterine cervix.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Co | 2014 |
[A case of a septic pulmonary embolism-related implanted central venous port].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venous; Catheters, I | 2013 |
Salvage radiation therapy and chemoradiation therapy for postoperative locoregional recurrence of esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinosarcom | 2014 |
Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 2014 |
Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2013 |
S-1 monotherapy as second- or third-line chemotherapy for unresectable and recurrent esophageal squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2013 |
Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations | 2014 |
Relapse-associated microRNA in gastric cancer patients after S-1 adjuvant chemotherapy.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Combinati | 2014 |
Outcome data of patients with peritoneal carcinomatosis from gastric origin treated by a strategy of bidirectional chemotherapy prior to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a single specialized center in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2014 |
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cispl | 2014 |
Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidin | 2014 |
Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy; | 2014 |
Docetexal plus S-1 versus oxaliplatin plus S-1 for first-line treatment of patients with advanced gastric cancer: a retrospective study.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Huma | 2014 |
Radiotherapy concurrent with S-1 and radiotherapy alone for T2N0 glottic carcinoma: a retrospective comparative study.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma; Chemoradiotherapy; Drug Combina | 2014 |
Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2014 |
Safety and efficacy of S-1 chemotherapy in recurrent and metastatic nasopharyngeal carcinoma patients after failure of platinum-based chemotherapy: multi-institutional retrospective analysis.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma; Disease Progression; Drug Combinations; Fem | 2014 |
Clinical significance of cytological status of peritoneal lavage fluid during intraperitoneal chemotherapy for gastric cancer with overt peritoneal dissemination.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th | 2015 |
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2014 |
Safety and pharmacokinetics of S-1 in a recurrent colon cancer patient with chronic myeloid leukemia treated with dasatinib: a case report.
Topics: Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colonic Neoplasms; Dasatinib; Drug Combinat | 2014 |
Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod | 2014 |
Combination Chemotherapy with S-1 and Oxaliplatin (SOX) as First-Line Treatment in Elderly Patients with Advanced Gastric Cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combin | 2015 |
Multicenter observational cohort study of post-operative treatment for completely resected non-small-cell lung cancer of pathological Stage I (T1 >2 cm and T2 in TNM classification version 6).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuva | 2015 |
[A case of hepatic metastases from colorectal cancer in a long-term survivor undergoing local combined modality therapy for repeated local recurrences].
Topics: Aged, 80 and over; Catheter Ablation; Combined Modality Therapy; Drug Combinations; Embolization, Th | 2014 |
[Complete response in a case of anastomotic recurrence of rectal cancer treated with S-1 monotherapy].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; Middle Aged; Neoplasm Recurrence | 2014 |
Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Combi | 2015 |
S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Com | 2016 |
[A Case of Unresectable Local Recurrence of Gastric Cancer Successfully Resected after Pre-Operative Chemotherapy with Trastuzumab].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; | 2015 |
Repeated Hepatectomy for Recurrent Intrahepatic Cholangiolocellular Carcinoma: Report of a Case.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cholangiocarcinoma; Deoxycyt | 2016 |
Usefulness of chemoradiotherapy for inoperable gastric cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2017 |
Achieved good response of S-1 and docetaxel combination chemotherapy in two patients with metastatic extramammary Paget's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Combinations; Fatal Outcome; H | 2017 |
Adjuvant S-1 chemotherapy after curative resection of gastric cancer in Chinese patients: assessment of treatment tolerability and associated risk factors.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Chemotherap | 2017 |
[A case report of S-1 single effective use as third-line chemotherapy and re-challenge in a recurrent squamous cell lung cancer patient].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; D | 2008 |
[A case of liver metastatic recurrence of bile duct cancer completely responding to single-drug S-1 chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Biomarkers, Tumor; Drug C | 2008 |
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antimetabolites, Antineoplastic; Bone Neoplasms; Bre | 2009 |
Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Comb | 2008 |
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy | 2009 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Mo | 2008 |
[A case of early recurrence with multiple liver metastases after curative operation of gastric cancer successfully treated by S-1/CDDP combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Drug Combination | 2008 |
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinati | 2009 |
S-1 monotherapy in patients with advanced biliary tract cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biliary Tract Neopl | 2009 |
Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Sq | 2009 |
[Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Anti | 2009 |
Can the 2-(13)C-uracil breath test be used to predict the effect of the antitumor drug S-1?
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon H | 2010 |
[Complete response by S-1 with multiple pulmonary metastases 4 years after lung resection-a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Drug Combinations; Humans; Lung Neo | 2009 |
[A case of cancer successfully treated by chemotherapy of S-1 as first-line chemotherapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Drug Combinations; Humans; | 2009 |
[A resected case of pathologically complete response of a pelvic recurrence from rectal cancer after chemoradiotherapy with S-1].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Middle Aged; Neoadjuvant Therapy; | 2009 |
[A case of locally recurrent rectal cancer responding to radiation and chemotherapy with S-1].
Topics: Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Combinations; Humans; Male; Middle | 2009 |
[A case of advanced gastric cancer with paraaortic lymph node recurrence reaching a long-term survival by S-1 chemotherapy].
Topics: Antimetabolites, Antineoplastic; Aorta, Abdominal; Chemotherapy, Adjuvant; Drug Combinations; Humans | 2009 |
[A case of advanced gastric cancer treated with S-1 and S-1/paclitaxel showing complete response twice].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2009 |
[A case of successful control of recurrent duodenal carcinoma receiving paclitaxel].
Topics: Antimetabolites, Antineoplastic; Carnitine O-Palmitoyltransferase; Drug Combinations; Duodenal Neopl | 2009 |
[A long-term survival case of liver metastasis of gastric cancer under interdisciplinary therapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2009 |
[A case of recurrence gastric cancer patient who was post operated and multi drug chemotherapy was effective for administration of S-1 and docetaxel combination therapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2009 |
[A case of complete response to S-1 therapy for multiple pulmonary recurrences of hepatocellular carcinoma after hepatic resection].
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Drug Combinations; Hepatectomy; Hu | 2009 |
[Combination of S-1 and paclitaxel for advanced/recurrent gastric cancer patients with peritoneal metastasis, feasibility study (OGSG0401)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |
[Liver metastasis from sigmoid colon cancer showed a complete response to S-1 after recurrence with FOLFOX6 treatment].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2010 |
[A successful case of S-1 chemotherapy for bilateral pulmonary recurrence of hepatocellular carcinoma long after hepatectomy].
Topics: Administration, Oral; Carcinoma, Hepatocellular; Drug Combinations; Hepatectomy; Humans; Liver Neopl | 2010 |
Focal dose escalation using FDG-PET-guided intensity-modulated radiation therapy boost for postoperative local recurrent rectal cancer: a planning study with comparison of DVH and NTCP.
Topics: Antimetabolites, Antineoplastic; Dose-Response Relationship, Radiation; Drug Combinations; Fluorodeo | 2010 |
Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Comb | 2010 |
[Results of chemotherapy in head and neck cancer patients with residual or recurrent tumors after initial treatment].
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Head | 2010 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent colonic cancer receiving combination chemotherapy of S-1 and irinotecan hydrochloride].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2010 |
[A case with local recurrence of rectal cancer that responded to S-1 and PSK with long-term complete response].
Topics: Adenocarcinoma, Mucinous; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 2010 |
Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcino | 2011 |
Chemosensitivity test for 5-fluorouracil and 5-chloro-2, 4-dihydroxypyridine predicts outcome of gastric cancer patients receiving S-1 postoperatively.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Combinations; Fem | 2010 |
[A case of capecitabine-resistant recurrent breast cancer found to be responsive to S-1].
Topics: Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Combinations; Drug Resistance, Neoplasm; Female; | 2010 |
[A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2010 |
[A case of type 4 gastric cancer with positive peritoneal lavage cytology, which relapsed at the peritoneum at the time of seven years and eight months after resection].
Topics: Adenocarcinoma, Scirrhous; Antimetabolites, Antineoplastic; Drug Combinations; Female; Gastrectomy; | 2010 |
[A case of advanced gastric cancer successfully treated with chemoradiotherapy targeting for recurrent lymph node metastasis].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
[A case of local relapsed rectal cancer responding to low-dose S-1].
Topics: Administration, Oral; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch | 2010 |
[A case report--intrahepatic arterial infusion with CDDP and S-1 administration can elicit long-term survival for the patient with recurrenced intrahepatic cholangiocarcinoma after resection].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2010 |
Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug C | 2011 |
Macroscopic tumor size as an independent prognostic factor for stage II/III gastric cancer patients who underwent D2 gastrectomy followed by adjuvant chemotherapy with S-1.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv | 2011 |
Good response chemotherapy for late-recurring gastric cancer in the gluteals, with peritoneal and retroperitoneal dissemination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Buttocks; Carcinoma, Signet Ring Cell; Cisplatin; Dr | 2011 |
Stereotactic radiosurgery in combination with chemotherapy as primary treatment for head and neck cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto | 2012 |
Second-line chemotherapy with paclitaxel and doxifluridine after failure of S-1 in elderly patients with unresectable advanced or recurrent gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc | 2012 |
S-1 monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck after progression on platinum-based chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug | 2011 |
Risk factors for peritoneal recurrence in stage II/III gastric cancer patients who received S-1 adjuvant chemotherapy after D2 gastrectomy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Co | 2012 |
[Development of oral drugs in the standard therapy for metastatic colorectal cancer patients].
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, | 2011 |
Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, In | 2012 |
Fluoropyrimidine plus cisplatin for patients with advanced or recurrent gastric cancer with peritoneal metastasis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Capecitabine; Cisplatin; Deoxy | 2013 |
An analysis of a second-line S-1 monotherapy for gemcitabine-refractory biliary tract cancer.
Topics: Aged; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; C | 2012 |
A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; | 2013 |
Leiomyosarcoma of the sigmoid colon with multiple liver metastases and gastric cancer: a case report.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2012 |
The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 2012 |
Adjuvant chemotherapy with an oral fluoropyrimidine, S-1, following reduced RADPLAT in advanced laryngeal cancer.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Chemotherapy, | 2012 |
Pharmaceutical care for patients undergoing s-1 plus Cisplatin therapy for unresectable recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatinine; Drug Combination | 2013 |
[Complete response in a case of recurrent gastric cancer treated with TS-1].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Drug Administration Sch | 2002 |
[Adverse reactions to TS-1 for outpatients with recurrent head and neck cancer].
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug Co | 2002 |
S-1 in the treatment of advanced and recurrent gastric cancer: current state and future prospects.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration Schedule; Drug | 2003 |
Longterm control of advanced and recurrent gastric cancer (ARGC) by S-1.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; D | 2003 |
[A patient with recurrent gastric cancer who developed TS-1 induced hand-foot syndrome].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Conjunctivitis; Drug Combinations; Foot Derma | 2003 |
[A case of recurrent early gastric cancer with peritonitis carcinomatosa successfully treated with TS-1].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Drug Administration Schedule; Drug Combina | 2003 |
[A clinical results of TS-1 in advanced and recurrent gastric cancer in our hospital].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration | 2003 |
[Clinical evaluation, including QOL of TS-1 for patients with locally advanced or recurrent gastric cancer at ambulatory setting].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Drug Administra | 2003 |
[TS-1 and lentinan combination immunochemotherapy for advanced or recurrent gastric cancer: a preliminary report].
Topics: Adjuvants, Immunologic; Adult; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; | 2003 |
[Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Combinatio | 2003 |
[Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administration Schedu | 2004 |
[A case of TS-1 resistant recurrent gastric cancer responding to TS-1 +CPT-11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug | 2004 |
[A case of recurrent gallbladder cancer responding to combination chemotherapy of TS-1 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Diarrhea | 2004 |
[A case of recurrent gastric cancer tolerant to TS-1 therapy successfully treated by TS-1 combined with docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Administrati | 2004 |
[A case of recurrent gastric cancer with peritoneal dissemination successfully treated with DJ stents against bilateral hydronephrosis and chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Combined M | 2004 |
[Two cases of advanced and recurrent gastric cancer treated with the combination of chemotherapy and radiation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Drug Combinati | 2004 |
[A case of long-term survivor with multiple pulmonary metastases of HCC after hepatic resection].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Drug Combinati | 2004 |
[Results of treatment of far advanced and recurrent stomach cancer with TS-1].
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Sched | 2005 |
[Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther | 2005 |
[Clinical study of TS-1 for inoperative and recurrent gastric cancer and evaluation of long survival cases].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Combinations; Female; Humans; | 2005 |
[Safety and efficacy of chemotherapy using TS-1 followed by paclitaxel for advanced or recurrent gastric cancer with peritoneal dissemination].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2005 |
[A case of recurrent pancreatic cancer responding to TS-1 combined gemcitabine chemotherapy after UFT combined gemcitabine chemotherapy resulting progressive disease].
Topics: Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Drug Administration Schedule; Drug Co | 2006 |
[Clinical results of single therapy with TS-1 for advanced/recurrent gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Drug Administration | 2006 |
[Clinical efficacy and safety of weekly paclitaxel therapy as second-line chemotherapy for patients with advanced and recurrent gastric cancer who were previously treated with TS-1 therapy].
Topics: Aged; Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Drug Administrat | 2006 |
A case of hepatocellular carcinoma with multiple lung, spleen, and remnant liver metastasis successfully treated by combination chemotherapy with the novel oral DPD-inhibiting chemotherapeutic drug S-1 and interferon-alpha.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Dihydrouracil Dehy | 2006 |
Combination therapy of S-1 and CDDP for patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2007 |
Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Creatinine; D | 2007 |
[Evaluation of combination therapy of high-dose toremifene and oral chemotherapy].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine | 2007 |
[Long-term results of S-1 administration as adjuvant chemotherapy for advanced head and neck cancer].
Topics: Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administratio | 2007 |
[A case of recurrence after resection of stage IV advanced bile duct cancer responding well to S-1/cisplatin combination chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy P | 2007 |
[Prolonged complete response obtained by single agent S-1 in a case of peritoneal metastasis from gastric remnant cancer].
Topics: Antimetabolites, Antineoplastic; Drug Combinations; Gastric Stump; Humans; Male; Middle Aged; Neopla | 2007 |
[Effect of S-1 in a patient with post-operative recurrence of carcinoma of the ampulla of Vater].
Topics: Ampulla of Vater; Antimetabolites, Antineoplastic; Common Bile Duct Neoplasms; Drug Combinations; Fe | 2007 |
[An elderly case of recurrent colon cancer responding to weekly S-1 chemotherapy leading to partial response].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; | 2008 |
[A case report-the marked response to S-1 + CDDP chemotherapy for post-operative local recurrence of advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Follow-Up Stud | 2007 |
[An elderly patient with recurrent rectal cancer successfully responded to S-1 combined with CPT-11].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonoscopy; Drug C | 2007 |
Long term survival on S-1 monotherapy in a patient with recurrent stage IV pancreatic cancer.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Humans; Male; Neoplasm Rec | 2008 |
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Cohort Studies; Drug Combinations; Female; | 2007 |
[Recurrent gallbladder carcinoma treated with combination chemotherapy with gemcitabine, CPT-11 and S-1--a successful case with metastatic tumors replaced by marked calcification].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla | 2008 |